Stabilization of substances in circulation

Bioconjugate Chemistry

Volumn 9, Issue 4, 1998, Pages 418-450

  Monfardini, Cristina ^a   Veronese, Francesco M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0032126044     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc970184f     Document Type: Review

References (478)

1. Duncan, R., and Kopecek, J. (1984) Soluble synthetic polymers as potential drug carriers. Adv. Polym. Sci. 57, 53-101.
2. Robert, K. Y., Cheng, Z., and Cheng, C. C. (1989) Delivery of anticancer drugs. Methods Find. Exp. Clin. Pharmacol. 11, 439-529.
3. Goddard, P. (1991) Therapeutic proteins-A pharmaceutical perspective. Adv. Drug Delivery Rev. 6, 103-131.
4. Nucci, M. L., Shorr, R., and Abuchoski, A. (1991) The therapeutic value of poly(ethylene glycol)-modified proteins. Adv. Drug Delivery Rev. 6, 133-151.
5. Pizzo, S. V. (1991) Preparation, in vivo properties and proposed clinical use of polyoxyethylene-modified tissue plasminogen activator and streptokinase. Adv. Drug Delivery Rev. 6, 153-166.
6. Wileman, T. E. (1991) Properties of asparaginase-dextran conjugates. Adv. Drug Delivery Rev. 6, 167-180.
7. Maeda, H. (1991) SMANCS and polymer conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Delivery Rev. 6, 181-202.
8. Sehon, A. H. (1991) Suppression of antibody responses by conjugates of antigens and monomethoxypoly(ethylene glycol). Adv. Drug Delivery Rev. 6, 203-217.
9. Duncan, R. (1992) Drug-polymer conjugates: potential for improved chemotherapy. Anti-Cancer Drugs 3, 175-210.
10. Delgado, C., Francis, G. E., and Fisher, D. (1992) The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carrier Syst. 9, 91-114.
11. Katre, N. V. (1993) The coniugation of proteins with polyethylene glycol and other polymers. Altering properties of proteins to enhance their therapeutic potential. Adv. Drug Delivery Rev. 10, 91-114.
12. Zalipsky, S. (1995) Chemistry of polyethylene glycol conjugates with biologically active molecules. Adv. Drug Delivery Rev. 16, 157-182.
13. Duncan, R., and Spreafico, F. (1994) Polymer Conjugates. Pharmacokinetic considerations for design and development. Clin. Pharmacokinet. 27, 290-306.
14. Putnam, D., and Kopecek, J. (1995) Polymer conjugates with anticancer activity. Adv. Polym. Sci. 122, 55-123.
15. Ringsdorf, H. (1975) Structure and properties of pharmacologically active polymers. J. Polym. Sci., Polym. Symp. 51, 135-153.
16. Marshall, J. J., Humpreys, J. D., and Abramson, S. L. (1977) Attachment of carbohydrate to enzymes increases their circulation lifetime. FEBS Lett. 83, 249-252.
17. 2 to soluble dextran. (i). Properties of conjugates and effects on plasma persistence in mice. Biochem. Pharmacol. 36, 105-112.
18. 2 to soluble dextran. (ii). In vivo distribution and fate of conjugates. Biochem. Pharmacol. 36, 113-121.
19. Sherwood, R. F., Baird, J. K., Atkinson, T., Wiblin, C. N., Rutte, D. A., and Ellwood, D. C. (1977) Enhanced plasma persistence of therapeutic enzymes by coupling to soluble dextran. Biochem. J. 164, 461-464.
20. Wileman, T. E., Foster, R. L., and Elliott, P. N. C. (1986) Soluble asparaginase-dextran conjugates show increased circulatory persistence and lowered antigen reactivity. J. Pharm. Pharmacol. 38, 264-271.
21. Wileman, T., Bennet, M., and Lilleyman, J. (1983) Potential use of an asparaginase-dextran conjugate in acute lymphoblastic leukemia. J. Pharm. Pharmacol. 35, 762-765.
22. Sprincl, L., Exner, J., Sterba, O., and Kopecek, J. (1976) New types of synthetic infusion solutions III. Elimination and retention of poly[N-(2-hydroxypropyl)methacrylamide] in a test organism. J. Biomed. Mater. Res. 10, 953-963.
23. Rihova, B., Kopecek, J., Ulbrich, K., and Chytry, V. (1985) Immunogenicity of N-(2-hydroxypropyl)methacrylarmde co-polymers. Makromol. Chem. (Suppl.) 9, 13-24.
24. Kopecek, J., and Bazilova, H. (1973) Poly[N-(2-hydroxypropyl)methacrylamide] 1. Radical polimerisation and co-polymerisation. Eur. Polym. J. 9, 7-14.
25. Strohalm, J., and Kopecek, J. (1978) Poly[N-(2-hydroxypropyl)methacrylamide] IV. Heterogeneous polimerisation. Angew. Makromol. Chem. 70, 109-118.
26. Rejmanova, P., Labsky, J., and Kopecek, J. (1977) Aminolysis of monomeric and polymeric p-nitrophenyl esters of methacryloylated amino acids. Makromol. Chem. 178, 2159-2168.
27. Ulbrich, K., Zacharieva, E. I., Obereigner, B., and Kopecek, J. (1980) Polymers containing enzymatically degradable bonds 5. Hydrophilic polymers degradable by papain. Biomaterials 1, 199-204.
28. Kopecek, J., and Duncan, R. (1987) Targetable polymeric prodrugs. J. Controlled Release 6, 315-327.
29. Rihova, B., Ulbrich, K., Strohalm, J., Vetvika, V., Bilej, M., Duncan, R., and Kopecek, J. (1989) Biocompatibility of N-(2-hydroxypropyl)methacrylamide copolymers containing adriamycin. Immunogenicity, effect on hematopoietic stem cells in bone marrow in vivo and effect of mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials 10, 335-342.
30. Kopecek, J. (1990) The potential of water-soluble polymeric carriers in targeted and site-specific drug delivery. J. Controlled Release 11, 279-290.
31. Kamei, S., and Kopecek, J. (1995) Prolonged blood circulation in rats of nanospheres surface-modified with semitelechelic poly[N-(2-hydroxypropyl)methacrylamide]. Pharm. Res. 12, 663-668.
32. Maeda, H., Ueda, M., Morinaga, T., and Matsumoto, T. (1985) Conjugation of poly(styrene-co-maleic acid) derivative to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties. J. Med. Chem. 28, 455-461.
33. Kobayashi, A., Oda, T., and Maeda, M. (1988) Protein binding of macromolecular anticancer agent SMANCS: characterization of poly(styrene-co-maleic acid) derivatives as an albumin binding ligand. J. Bioact. Compat. Polym. 3, 319-333.
34. Breslow, D. S. (1976) Biologically active synthetic polymers. Pure Appl. Chem. 46, 103-113.
35. Breslow, D. S., Edwards, E. I., and Newborg, N. R. (1973) Divinyl ether maleic anhydride (pyran) copolymer used to demonstrate the effect of molecular weight on biological activity. Nature 246, 160-162.
36. Hirano, T., Ohashi, S., Morimoto, K., Tsuda, T., Kobayashi, T., and Tsuksgoshi, S. (1986) Synthesis of antitumor-active conjugates of adriamicyn or daunomicyn with the copolymer of divinyl ether and maleic anhydride. Makromol. Chem. 187, 2815-2824.
37. Hirano, T., Todoroki, S., Kato, H., Yamamoto, H., Caliceti, P., Veronese, F. M., Maeda, H., and Ohashi, S. (1994) Synthesis of the conjugate of superoxide dismutase with the copolymer of divinyl ether and maleic anhydride retaining enzymatic activity. J. Controlled Release 28, 203-209.
38. Ravin, H. A., Seligman, A. M., and Fine, J. (1952) Polivinylpyrrolidone as plasma expander: studies on its excretion, distribution and metabolism. N. Engl. J. Med. 247.24, 921-929.
39. Haaf, A. S., and Straub, F. (1985) Polymers of N-vinylpyrrolidone: synthesis, characterization and uses. Polym. J. 17.1, 143-152.
40. Von Specht, B. W., Seinfeld, H., and Brendel, W. (1973) Polivinylpyrrolidone as a soluble carrier of proteins. Hope-Seyler's Z. Physiol. Chem. 354, 1659-1660.
41. Andreani, F., Salatelli, E., and Ferruti, P. (1986) Synthesis of end-capped functionalized PVP oligomers. J. Bioact. Compat. Polym. 1, 72-80.
42. Veronese, F. M., Sartore, L., Caliceti, P., Schiavon, O., Ranucci E., and Ferruti, P. (1990) Hydroxy-terminated polivinylpyrrolidone for the modification of polypeptides. J. Bioact. Compat. Polym. 5, 167-178.
43. Sartore L., Ranucci, E., Ferruti, P., Caliceti, P., Schiavon, O., and Veronese, F. M. (1994) Low molecular weight end-functionalized poly(N-vinylpyrrolidinone) for the modification of polypeptide amino groups. J. Bioact. Compat. Polym. 9, 411-427.
44. Kopececk, J., Bacik, J., and Sprincl, L. (1973) Soluble hydrophilic polymers. German Patent 2,309,894.
45. Nitto Electric Industrial Co., Ltd. (1985) Hydrophilic materials for transdermal patches. JP 6041,968.
46. Takashi, K., Saburo, O., Shoichi, T., and Keisuke, S. (1985) Transdermal pharmaceutical containing dihydropyridine derivatives. JP 60,166,61.
47. Ranucci, E., Spagnoli, G., Sartore, L., and Ferruti, P. (1994) Synthesis and molecular weight characterization of low molecular weight end-functionalized poly(4-acryloylmorpholine). Macromol. Chem. Phys. 195, 3469-3479.
48. Bailey, J., and Koleske, J. V., Eds. (1976) Poly(ethyleneoxide), Academic Press, New York.
49. Powell, G. M. (1980) Polyethylene glycol. In Handbook of Water Soluble Gums and Resins (R. L. Davidson, Ed.) pp 18-1-18-31, McGraw-Hill, New York.
50. Mutter, M., and Bayer, E. (1979) The liquid-phase method for peptide synthesis. In The Peptides (E. Gross and J. Meienhofer, Eds.) pp 285-332, Academic Press, New York.
51. Dreborg, S., and Akerblom, E. B. (1990) Immunotherapy with monomethoxypolyethylene glycol modified allergenes. Crit. Rev. Ther. Drug Carrier Syst. 6, 315-365.
52. Yamaoka, T., Tabata, Y., and Ikada, Y. (1994) Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration in mice. J. Pharm. Sci. 83, 601-606.
53. Harris, J. M., Ed. (1992) Poly(ethylene glycol) Chemistry: Biotechnical and Biomedical Applications, Plenum Press, New York.
54. Murakami, Y., Tabata, Y., and Ikada, Y. (1997) Tumor accumulation of poly(ethylene glycol) with different molecular weights after intravenous injection. Drug Delivery 4, 23-31.
55. Johansson, G., and Joelsson, M. (1985) Preparation of Cibacron Blue F3G-A-polyethylene glycol in large scale for use in affinity partitioning. Biotechnol. Bioeng. 27, 621-625.
56. Khachadurian, A. K., Fung, C. H., Van Es, T., and Davis, F. F. (1981) Polyoxyethylated cholesterol derivatives: organic synthesis, cellular uptake and effect on methabolism in cultured skin fibroblasts. Biochim. Biophys. Acta 665, 434-441.
57. Zalipsky, S., Gilon, C., and Zilkha, A. (1983) Attachment of drugs to polyethylene glycols. Eur. Polym. J. 19, 1177-1183.
58. Cecchi, R., Rusconi, L., Tanzi, M. C., Danusso, F., and Ferruti, P. (1981) Synthesis and pharmacological evaluation of poly(oxyethylene) derivatives of 4-isobutylphenyl-2-propionic acid (Ibuprofen). J. Med. Chem. 24, 622-625.
59. Ghedini, N., Zecchi, V., Tartarini, A., Scapini, G., Andrisano, V., and Ferruti, P. (1986) Synthesis and partition profiles of nicotinic acid derivatives with oligomeric carriers. J. Controlled Release 3, 185-191.
60. Dal Pozzo, A., Acquasaliente, M., Donzelli, G., Delor, F., and Ferruti, P. (1986) Synthesis and antimicrobial properties of new aroyl-acrylic esters of polyethylene glycols. Farmaco 41, 622-629.
61. Zalipski, S., Gilon, C., and Zilkha, A. (1984) Esterification of polyethylene glycols. J. Macromol. Sci. Chem. A21, 839-845.
62. Khue, N. V., and Galin, J. C. (1985) Antiinflammatory polymer-bound steroids for topical applications I. Synthesis and characterization. J. Appl. Polym. Sci. 30, 2761-2778.
63. Zalipsky, S. (1995) Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. Bioconjugate Chem. 6, 150-165.
64. Herman, S., Hooftman, G., and Schacht, E. (1995) Poly(ethylene glycol) with reactive endgroups: I. Modification of proteins. J. Bioact. Compat. Polym. 10, 145-187.
65. Buckmann, A. F., Morr, M., and Kula, M. R. (1987) Preparation of technical grade polyethylene glycol (PEG) (Mr 20,000)-N6-(2-aminoethyl)-NADH by a procedure adaptable to large scale synthesis. Biotechnol. Appl. Biochem. 9, 258-268.
66. Bayer, E., Zheng, H., and Geckeler, K. (1982) Functionalization of soluble polymers 4. Synthesis of dichloro- and di-(4-formylphenyloxyethyl) poly(oxyethylene). Polym. Bull. 8, 585-592.
67. Buckmann, A., Morr, M., and Johansson, G. (1981) Functionalization of poly(ethylene glycol) and monomethoxy-poly-(ethylene glycol). Makromol. Chem. 182, 1379-1384.
68. Ziegast, G., and Pfannemuller, B. (1984) Linear and starshaped hybrid polymers 1. A new method for the conversion of hydroxyl end groups of poly(oxyethylene) and other polyols into amino end groups. Makromol. Chem. Rapid Commun. 5, 363-371.
69. Swamikannu, A. X., and Litt, M. H. (1984) Preparation and characterization of p-toluene sulfonyl ester and amino derivatives of tri- and poly(ethylene glycol). J. Polym. Sci., Polym. Chem. Ed. 22, 1623-1632.
70. De Vos, R. J., and Goethals, E. J. (1985) Convenient synthesis of α-tosyl-ω-tosyloxypoly(oxyethylene). Makromol. Chem. Rapid Commun. 6, 53-56.
71. ω-dithiasuccinoyl (Dts) amino acids and dipeptides: Application of polyethylene glycol as a carrier for functional purification. Int. J. Pept. Protein Res. 30, 740-783.
72. Harris, J. M., Struck, E. C., Case, M. G., Paley, M. S., Yalpani, M., Van Alstine, J. M., and Brooks, D. E. (1984) Synthesis and characterization of poly(ethylene glycol) derivatives. J. Polym. Sci., Polym. Chem. Ed. 22, 341-352.
73. Pillai, V. N. R., Mutter, M., Bayer, E., and Gatfield, I. (1980) New, easily removable poly(ethylene glycol) supports for the liquid-phase method of peptide synthesis. J. Org. Chem. 45, 5364-5370.
74. Sano, A., Maeda, H., Kai, Y., and Ono, K. (1989) Polyethylene glycol derivatives, modified peptides and production thereof. Eur. Pat. Appl. 0340741.
75. Harris, J. M., Dust, J. M., McGill, A., Harris, P. A., Edgel, M. J., Herrati, R. S., Karr, L. J., and Donnelly, D. L. (1991) New polyethylene glycol for biomedical applications. In Water-Soluble Polymers (S. W. Shalaby, C. L. McCormic, and G. B. Butler, Eds.) pp 418-429, ACS Symposium Series, American Chemical Society, Washington, DC.
76. Nillsson, K., and Mosbach, K. (1984) Immobilization of ligands with organic sulfonyl chlorides. Methods Enzymol. 104, 56-69.
77. Delgado, C., Patel, J. N., Francis, G. E., and Fisher, D. (1990) Coupling of poly(ethylene glycol) to albumin under very mild conditions by activation with tresyl chloride: characterization of the conjugate by partitioning in aqueous two-phase systems. Biotechnol. Appl. Biochem. 12, 119-128.
78. Knusli, C., Delgado, C., Malik, F., Domine, M., Tejedor, C., Irvine, A. E., Fisher, D., and Francis, G. E. (1992) Polyethylene glycol modification of granulocyte-macrophage colony stimulating factor (GM-CSF) enhances neutrophil priming activity but not colony stimulating activity. Br. J. Haematol. 82, 654-663.
79. Yoshinga, K., and Harris, J. M. (1989) Effects of coupling chemistry on the activity of poly(ethylene glycol)-modified alkaline phosphatase. J. Bioact. Compat. Polym. 4, 17-24.
80. Loccufier, J., Crommen, J., Vandorpe, J., and Schacht, E. (1991) End-group modification of α-hydro-ω-methoxypoly-(oxyethylene), 2: Facile methods for the introduction of an α-amino end-group. Makromol. Chem. Rapid Commun. 12, 159-165.
81. Leonard, M., and Dellacherie, E. (1988) Synthesis and characterization of a polyoxyethylene derivative for the affinity labeling of human hemoglobin. Makromol. Chem. 189, 1809-1817.
82. Zalipsky, S., Chang, J. L., Albericio, F., and Barany, G. (1994) Preparation and applications of polyethylene glycolpolystyrene graft resin supports for solid-phase peptide synthesis. React. Polym. 22, 243-258.
83. Pollak, A., and Witeside, G. M. (1976) Organic synthesis using enzymes in two-phase aqueous ternary systems. J. Am. Chem. Soc. 98, 289-291.
84. Rozzell, D. (1987) Immobilized aminotransferases for amino acid production. Methods Enzymol. 136, 479-497.
85. Persson, L. O., and Olde, B. (1988) Synthesis of ATP-polyethylene glycol and ATP-dextran and their use in the purification of phosphoglycerate kinase from spinach chloroplasts using affinity partitioning. J. Chromatogr. 457, 183-193.
86. Zalipsky, S., Lee, C., and Menon-Rudolph, S. (1992) Hydrazine containing conjugates of polypeptides and glycopeptides with polymers. PCT Int. Appl. WO 9216555.
87. Zalipsky, S., and Menon-Rudolph, S. (1997) Hydrazide derivatives of poly(ethylene glycol) and their bioconjugates. In Poly(ethylene glycol): Chemistry and Biological Applications (J. M. Harris and S. Zalipsky, Eds.) pp 318-341, American Chemical Society, Washington, DC.
88. Andresz, H., Richter, G. C., and Pfannemuller, B. (1978) Chemische Synthese verzweigter Polysaccharide, 5: Kopplung von Oligosacchariden und Amilose an verschiedene Trager durch Hydrazonbindung. (Chemical synthesis of branched polysaccharides, 5. Coupling of oligosaccharides and amylose to various carriers by hydrazone linkage). Makromol. Chem. 179, 301-312.
89. Herron, J. N., Gentry, C. A., Davies, S. S., and Lin, J. N. (1994) Antibodies as targeting moieties: affinity measurements, conjugation chemistry, and applications in immunoliposomes. J. Controlled Release 28, 155-166.
90. Harris, J. M., Herati, M. R. S., Sather, P. J., Brooks, D. E., and Fyles, T. M. (1992) Synthesis of new poly(ethylene glycol) derivatives. In Poly(ethylene glycol) Chemistry: Biotechnical and Biomedical Applications (J. M. Harris, Ed.) pp 371-381, Plenum Press, New York.
91. Johansson, G. (1986) Effects of poly(ethylene glycol)-bound alcohols and amines on the partition of albumins and thylakoid membranes in an aqueous two-phase system. J. Chromatogr. 368, 309-317.
92. Zalipsky, S., and Barany, G. (1990) Facile synthesis of α-hydroxy-ω-carboxymethylpolyethylene oxide. J. Bioact. Compat. Polym. 5, 227-231.
93. Royer, G., and Anantharmaiah, G. M. (1979) Peptide synthesis in water and the use of immobilized carboxypeptidase Y for deprotection. J. Am. Chem. Soc. 101, 3394-3396.
94. Geckeler, K., and Bayer, E. (1980) Functionalization of soluble polymers 3. Preparation of carboxy-telechelic polymers. Polym. Bull. 3, 347-352.
95. Joppich, M., and Luisi, P. L. (1979) Peptides flanked by two polymers chains, 1. Synthesis of glycyl-L-tryptophylglycine substituted by poly(ethylene oxide) at both the carboxy and amino end groups. Makromol. Chem. 180, 1381-1384.
96. Ferruti, P., Tanzi, M. C., Rusconi, L., and Cecchi, R. (1981) Succinic half-esters of poly(ethylene glycol)s and their benzotriazole and imidazole derivatives as oligomeric drug-binding matrices. Makromol. Chem. 182, 2183-2192.
97. Zalipsky, S. (1993) Synthesis of an end-group functionalized polyethylene glycol-lipid conjugate for preparation of polymer-grafted liposomes. Bioconjugate Chem. 4, 296-299.
98. Zalipsky, S., and Barany, G. (1986) Preparation of polyethylene glycol derivatives with two different functional groups at the termini. Polym. Prepr. (Am. Chem. Soc., Div. Polym. Chem.) 27 (1), 1-2.
99. Ouchi, T., Banba, T., Masuda, H., Matsumoto, T., Suzuki, S., and Suzuki, M. (1991) Design of chitosan-5FU conjugate exhibiting antitumor activity. J. Macromol. Sci., Chem. 28, 959-975.
100. Zalipsky, S., and Lee, C. (1992) Use of functionalized polyethylene glycols for modification of polypeptides. In Poly-(ethylene glycol) Chemistry: Biotechnical and Biomedical Applications (J. M. Harris, Ed.) pp 347-370, Plenum Press, New York.
101. Boccu', E., Largajolli, R., and Veronese, F. M. (1983) Coupling of monomethoxypolyethylene glycols to proteins via active esters. Z. Naturforsch. 38C, 94-99.
102. Klibanov, A. L., Maruyama, K., Torchilin, V. P., and Huang, L. (1990) Amphipathic polyethylene glycols effectively prolong the circulation time of liposomes. FEBS Lett. 268, 235-237.
103. Blume, G., Cevc, G., Grommelin, M. D. J. A., Bakker-Woudenberg, I. A. J. M., Kluft, C., and Storm, G. (1993) Specific targeting of poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim. Biophys. Acta 1149, 180-184.
104. Sartore, L., Caliceti P., Schiavon, O., and Veronese, F. M. (1991) Enzyme modification by MPEG with an amino acid or peptide as spacer arms. Appl. Biochem. Biotechnol. 27, 45-54.
105. Sartore, L., Caliceti, P., Schiavon, O., Monfardini, C., and Veronese, F. M. (1991) Accurate evaluation method of the polymer content in monomethoxy(polyethylene glycol) modified proteins based on amino acid analysis. Appl. Biochem. Biotechnol. 31, 213-222.
106. Beauchamp, C. O., Gonias, S. L., Menapace, D. P., and Pizzo, S. V. (1983) A new procedure for the synthesis of polyethylene glycol-protein adducts. Effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin and α2-macroglobulin. Anal. Biochem. 131, 25-33.
107. Veronese, F. M., Largajolli, R., Boccu', E., Benassi, C. A., and Schiavon, O. (1985) Surface modification of proteins: activation of monomethoxy-polyethylene glycols by phenylchloroformates and modification of ribonuclease and superoxide dismutase. Appl. Biochem. Biotechnol. 11, 141-152.
108. Zalipsky, S., Seltzer, R., and Menon-Rudolph, S. (1992) Evaluation of a new reagent for covalent attachment of polyethylene glycol to proteins. Biotechnol. Appl. Biochem. 15, 100-114.
109. Chiu, H. C., Zalipsky, S., Kopeckova, P., and Kopecek, J. (1993) Enzymatic activity of chymotrypsin and its poly-(ethylene glycol) conjugates toward low and high molecular weight substrates. Bioconjugate Chem. 4, 290-295.
110. Zalipsky, S., Seltzer, R., and Nho, K. (1991) Succinimidyl carbonates of polyethylene glycol: useful reactive polymers for preparation of protein conjugates. In Polymeric Drugs and Drug Delivery Systems (R. L. Dunn and R. M. Ottenbrite, Eds.) pp 91-100, American Chemical Society, Washington, DC.
111. Sirokman, G., and Fasman, G. D. (1993) Refolding and proton pumping activity of a polyethylene glycol-bacterio-rhodopsin water-soluble conjugate. Protein Sci. 2, 1161-1170.
112. Poiani, J. G., Gean, K. F., Fox, J. D., Kohn, J., and Riley, D. J. (1993) Antifibrotic effect of a proline analogue delivered in liposomes to cells in culture. Amino Acids 4, 237-248.
113. Abuchowski, A., Van Es, T., Palczuk, N. C., and Davis, F. F. (1977) Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252, 3578-3581.
114. Ashihara, Y., Kono, T., Yamazaki, S., and Inada, Y. (1978) Modification of E. coli L-asparaginase with polyethylene glycol: Disappearance of binding ability to anti-asparaginase serum. Biochem. Biophys. Res. Commun. 83, 385-391.
115. Ono, K., Kai, Y., Maeda, H., Samizo, F., Sakurai, K., Nishimura, H., and Inada, Y. (1991) Selective synthesis of 2,4-bis(O-methoxypolyethylene glycol)-6-chloro-s-triazine as a protein modifier. J. Biomater. Sci., Polym. Ed. 2, 61-65.
116. Paley, M. S., and Harris, J. M. (1987) Synthesis of the aldehyde of oligomeric polyoxyethylene. J. Polym. Sci., Part A: Polym. Chem. 25, 2447-2454.
117. Topchieva, I. N., Kuzaev, A. I., and Zubov, V. P. (1988) Modification of polyethylene glycol. Eur. Polym. J. 24, 899-904.
118. Wirth, P., Souppe, J., Tritsch, D., and Biellmann, J. F. (1991) Chemical modification of horseradish peroxidase with ethanal-methoxypolyethylene glycol: solubility in organic solvents, activity, and properties. Bioorg. Chem. 19, 133-142.
119. Chamow, S. M., Kogan, T. P., Venuti, M., Gadek, T., Harris, R. J., Peers, D. H., Mordenti, J., Shak, S., and Ashkenazi, A. (1994) Modification of CD4 immunoadhesin with monomethoxypoly(ethylene glycol)aldehyde via reductive alkylation. Bioconjugate Chem. 5, 133-140.
120. Bayer, E., Zheng, H., and Geckeler, K. (1985) Functionalization of soluble polymers, 6. Preparation and kinetic aspects of linear, hydrophilic aldehydes based on poly-(oxyethylene). Polym. Bull. 13, 431-434.
121. Vandoorne, F., Loccufier, J., and Schacht, E. (1989) Functionalization of α-hydrogen-ω-methoxypoly(oxyethylene), 1: A new method for the conversion of hydroxyl end groups into aldehyde groups. Makromol. Chem. Rapid Commun. 10, 271-275.
122. Nathan, A., Zalipsky, S., Erthel, S. I., Agathos, S. N., Yarmusch, M. L., and Kohn, J. (1993) Copolymers of lysine and polyethylene glycol: A new family of functionalized drug carriers. Bioconjugate Chem. 4, 54-62.
123. Mathis, R., Hubert, P., and Dellacherie, E. (1985) Polyethylene oxyde: a ligand for mild hydrophobic interaction chromatography? J. Chromatogr. 347, 291-296.
124. Bergstrom, K., Holmberg, K., Safrani, A., Hoffman, A., Edgell, M. J., Kozlowski, A., Hovanes, B. A., and Harris, J. M. (1992) Reduction of fibrinogen adsorption on PEG-coated polystyrene. J. Biomed. Mater. Res. 26, 779-790.
125. Pitha, J., Kociolek, K., and Caron, M. G. (1979) Detergents linked to polysacchrides: Preparation and effects on membranes and cells. Eur. J. Biochem. 94, 11-18.
126. Garman, A. J., and Kalindijan, S. B. (1987) The preparation and properties of novel reversible polymer-protein conjugates. 2-ω-methoxypolyethylene (5000) glycoxymethylene-3-methylmaleyl conjugates of plasminogen activator. FEBS Lett. 223, 361-365.
127. Ueno, H., and Fujino, M. (1987) Chemically modified protein and production thereof. Eur. Pat. Appl. 0236987.
128. Kuan, C. T., Wang, Q. C., and Pastan, I. (1994) Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner. J. Biol. Chem. 269, 7610-7616.
129. Goodson, R. J., and Katre, N. V. (1990) Site-directed PEGylation of recombinant interleukin-2 at its glycosilation site. Bio/Technolgy 8, 343-346.
130. Morpurgo, M., Veronese, F. M., Kachensky, D., and Harris, J. M. (1996) Preparation and characterization of poly-(ethylene glycol) vinyl sulfone. Bioconjugate Chem. 7, 363-368.
131. Atassi, M. Z. (1977) Chemical modification and cleavage of proteins and chemical strategy in immunochemical studies of proteins. In Immunochemistry of Proteins (M. Z. Atassi, Ed.) pp 1-161, Plenum Press, New York.
132. Huang, Y. H., Li, Z. M., and Morawetz, H. (1985) The kinetics of the attachment of polymer chains to reactive latex particles and the resulting latex stabilization. J. Polym. Sci., Polym. Chem. Ed. 23, 795-799.
133. Monfardini, C., Schiavon, O., Caliceti, P., Morpurgo, M., Harris, J. M., and Veronese, F. M. (1995) A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjugate Chem. 6, 62-69.
134. Matsushima, A., Sasaki, H., Kodera, Y., and Inada, Y. (1992) Reduction of immunoreactivity of bovine serum albumin conjugated with polyethylene glycol in relation to its esterase activity. Biochem. Int. 26, 485-490.
135. Inada, Y., Furukawa, M., Sasaki, H., Kodera, Y., Hiroto, M., Nishimura, H., and Matsushima, A. (1995) Biomedical and biotechnological applications of PEG-and PM-modified proteins. Trends Biotechnol. 13, 86-91.
136. Nathan, A., Bolikal, D., Vyavahare, N., Zalipsky, S., and Kohn, J. (1992) Hydrogels based on water-soluble poly(ether urethane) derived from L-lysine and poly(ethylene glycol). Macromolecules 25, 4476-4484.
137. Yokoyama, M., Kwon, G. S., Okano, T., Sakurai, Y., Seto, T., and Kataoka, K. (1992) Preparation of micelles-forming polymer-drug conjugates. Bioconjugate Chem. 3, 295-301.
138. Bengs, H., Bayer, U., Krone, V., Lill, N., Sandow, J., and Walch, A. (1996) Polytartrate-a new biodegradable polymer. Proc. Int. Symp. Controlled Release Bioact. Mater., 23rd, 23-24.
139. Papisov, M., Garrido, L., Poss, K., Wright, C., Weisslender, R., and Brady, T. J. (1996) A long-circulating polymer with hydrolizable main chain. Proc. Int. Symp. Controlled Release Bioact. Mater., 23rd, 107-108.
140. Giammona, G., Carlisi, B., Cavallaro, G., Pitarresi, G., and Spampinato, S. (1994) A new water-soluble synthetic polymer, α,β-polyasparthydrazide, as potential plasma expander and drug carrier. J. Controlled Release 29, 63-72.
141. Pitarresi, G., Tomarchio, V., Cavallaro, G., and Giammona, G. (1996) α,β-poly(N-hydroxyethyl)-DL-asparthamide hydrogels as drug delivery devices. J. Bioact. Compat. Polym. 11, 328-340.
142. Vilaseca, L. A., Rose, K., Werlen, R., Meunier, A., Offord, R. E., Nichols, C. L., and Scott, W. L. (1993) Protein conjugates of defined structure: synthesis and use of a new carrier molecule. Bioconjugate Chem. 4, 515-520.
143. Schacht E. H., and Hoste, K. (1997) Poly(ethylene glycol)-grafted polymers as drug carriers. In Poly(ethylene glycol): Chemistry and Biological Applications (J. M. Harris and S. Zalipsky, Eds.) pp 297-315, American Chemical Society, Washington, DC.
144. Topchieva, I. N. (1997) Covalent and noncovalent adducts of proteins with water-soluble poly(alkylene oxides). In Poly-(ethylene glycol): Chemistry and Biological Applications (J. M. Harris and S. Zalipsky, Eds.) pp 193-206, American Chemical Society, Washington, DC.
145. Hoste, K., Bruneel, D., De Marre, A., De Schrijver, F., and Schacht, E. (1994) Synthesis and characterization of poly-(oxyethylene) modified dextrans. Macromol. Chem. Rapid Commun. 15, 697-704.
146. 5N-(2-hydroxyethyl-L-glutamine]. J. Bioact. Compat. Polym. 11, 85-99.
147. Gayet, J. C., and Fortier, G. (1996) High water content BSA-PEG hydrogels for controlled release device: evaluation of the drug release properties. J. Controlled Release 38, 177-184.
148. Ajisaka, K., and Iwashita, Y. (1980) Modification of human hemoglobin with polyethylene glycol: a new candidate for blood substitute. Biochem. Biophys. Res. Commun. 97, 1076-1081.
149. Boccu', E., Velo, G. P., and Veronese, F. M. (1982) Pharmacokinetic properties of polyethylene glycol derivatized superoxide dismutase. Pharmacol. Res. Commun. 14, 113-120.
150. Rajagopalan, S., Gonias, S. L., and Pizzo, S. V. (1985) A nonantigenic covalent streptokinase-polyethylene glycol complex with plasminogen activator function. J. Clin. Invest. 75, 413-419.
151. Sherwood, R. F., Baird, J. K., Atteinson, T., Wiblin, C. N., Rutter, D. A., and Ellwood, D. C. (1977) Enhanced plasma persistence of therapeutic enzymes by coupling to soluble dextran. Biochem. J. 164, 461-464.
152. Takakura, T., Kanedo, Y., Fujita, T., Hashida, M., Maeda, H., and Sezaki, H. (1989) Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran. I. Synthesis and characterization. J. Pharm. Sci. 78, 117-121.
153. Takakura, T., Fujita, T., Hashida, M., Maeda, H., and Sezaki, H. (1989) Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran. II. Biopharmaceutical and pharmacological properties. J. Pharm. Sci. 78, 219-222.
154. Fujita, T., Nishikawa, M., Tamaki, C., Takakura, Y., Hashida, M., and Sezaki, H. (1992) Targeted delivery of human recombinant superoxide dismutase by chemical modification with mono- and polysaccharides derivatives. J. Pharmacol. Exp. Ther. 263, 971-978.
155. Tabata, Y., Uno, K., Ikada, Y., Kishida, T., and Shigeru, M. (1993) Potentiation of in vivo antitumor effects of recombinant interleukin-1α by gelatin conjugation. Jpn. J. Cancer Res. 84, 681-688.
156. Shin, Y. H., Kojima, Y., Maeda, H., and Otagiri, M. (1996) Conjugation of succinylated gelatin to soybean trypsin inhibitor. J. Bioact. Compat. Polym. 11, 3-16.
157. Remy, M. H., and Poznansly, M. J. (1978) Immunogenicity and antigenicity of soluble cross-linked enzyme/albumin polymers: advantages for enzyme therapy. Lancet 2, 68-70.
158. Paige, A. G., Whitcomb, K. L., Liu, J., and Kinstler, O. (1995) Prolonged circulation of recombinant human granulocyte-colony stimulating factor by covalent linkage to albumin through a heterobifunctional polyethylene glycol. Pharmacol. Res. 12, 1883-1888.
159. Nakajima, N., Ishihara, K., Sugimoto, M., Sumi, H., Mikuni, K., and Hamada, H. (1996) Chemical modification of earthworm fibrinolytic enzyme with human serum albumin fragment and characterization of the protease as a therapeutic enzyme. Biosci., Biotechnol., Biochem. 60, 293-300.
160. Maeda, H., Takeshita, J., and Kanamaru, R. (1979) A lipophilic derivative of neocarzinostatin. A polymer conjugation of antitumor protein antibiotic. Int. J. Pept. Protein Res. 14, 81-87.
161. Maeda, H. (1997) Pharmacological uniqueness and clinical effects of neocarzinostatin. In Neocarzinostatin: the past, present, and future of an anticancer drug (H. Maeda, K. Edo, and N. Ishida, Eds.) pp 205-226, Springer-Verlag, Tokyo.
162. Ogino, T., Inoue, M., Ando, Y., Arai, M., Maeda, H., and Morino, Y. (1988) Chemical modification of superoxide dismutase. Extension of plasma half-life of the enzyme through its reversible binding to the circulating albumin. Int. J. Pept. Protein Res. 32, 153-159.
163. Maeda, H., Oda, T., Matsumura, Y., and Kimura, M. (1988) Improvement of pharmacological properties of protein drug by tailoring with synthetic polymers. J. Bioact. Compat. Polym. 3, 27-43.
164. Caliceti, P., Schiavon, O., Hirano, T., Ohashi, S., and Veronese, F. M. (1996) Modification of physico-chemical and biopharmaceutical properties of superoxide dismutase by conjugation to the co-polymer of divinyl ether and maleic anhydride. J. Controlled Release 39, 27-34.
165. Geiger, B., von Specht, B. U., and Arnon, R. (1977) Stabilization of human beta-D-N-acetylhexosaminidase A towards proteolytic inactivation by coupling it to poly(N-vinylpyrrolidone). Eur. J. Biochem. 73, 141-147.
166. Veronese, F., Schiavon, O., and Caliceti, P. (1997) Protein delivery: PVP as new polymer for protein conjugation. Proc. Int. Symp. Controlled Release Bioact. Mater., 24th, 507-508.
167. Caliceti, P., Schiavon, O., Morpurgo, M., and Veronese, F. M. (1995) Physico-chemical and biological properties of monofunctional hydroxy terminating poly(N-vinylpyrrolidone) conjugated superoxide dismutase. J. Bioact. Compat. Polym. 10, 103-120.
168. Veronese, F. M., Largajolli, R., Visco, C., Ferruti, P., and Miucci, A. (1985) Surface modification of proteins by covalent binding of acrylic polymers. Appl. Biochem. Biotechnol. 11, 269-277.
169. Veronese, F. M., Visco, C., Massarotto, S., Benassi, C. A., and Ferruti, P. (1987) New acrylic polymers for surface modification of enzymes of therapeutic interest and for enzyme immobilization. Ann. N.Y. Acad. Sci. 501, 444-448.
170. Brucato, F. H., and Pizzo, S. V. (1990) Catabolism of streptokinase and polyethylene glycol-streptokinase: evidience for transport of intact forms through the bilary system in the mouse. Blood 76, 73-79.
171. Pyatak, P. S., Abuchowski, A., and Davis, F. F. (1980) Preparation of polyethylene glycol: superoxide dismutase adduct, and an examination of its blood circulatory life and anti-inflammatory activity. Res. Commun. Chem. Path. Pharmacol. 29, 113-127.
172. Maksimenko, A. V., Petrov, A. D., Caliceti, P., Konovalova, G. G., Grigoryeva, E. L., Schiavon, O., Tischenko, E. G., Lankin, V. Z., and Veronese, F. M. (1995) Biodistribution of a polyethylene glycol-modified superoxide dismutase in mice and its effect on myocardial ischemia treatment in rats. Drug Delivery 2, 39-43.
173. Savoca, K. V., Davis, F. F., van Es, T., McCoy, J. R., and Palczuk, N. C. (1984) Cancer therapy with chemically modified enzymes. II. The therapeutic effectiveness of arginase and arginase modified by covalent attachment of polyethylene glycol, on the Taper liver tumor and the L5178Y murine leukemia. Cancer Biochem. Biophys. 7, 261-268.
174. Knauf, M. J., Bell, D. P., Hirtzer, P., Luo, Z. P., Young, J. D., and Katre, N. V. (1988) Relationship of effective molecular size to systemic clearance in rats of recombinant interleukine-2 chemically modified with water-soluble polymers. J. Biol. Chem. 263, 15064-15070.
175. Katre, N. V., Knauf, M., and Thomson, J. (1987) Tumor Necrosis Factor-Formulation and preparation. EP 0247860.
176. Tsutsumi, Y., Nakagawa, S., and Mayumi, T. (1996) Molecular design of hybrid cytokines with water soluble polymers. Proc. Int. Symp. Controlled Release Bioact. Mater., 23rd, 871-872.
177. Hiratani, H. (1986) Long-Acting Composition. U.S. Patent 4,609,546.
178. Shadle, P. J., Koths, K. E., Moreland, M., and Katre, N. (1989) Conjugation of polymer to colony stimulating factor-1. U.S. Patent 4,847,325.
179. Tanaka, H., Satake-Ishikawa, R., Ishikawa, M., Matsuki, S., and Asano, K. (1991) Pharmacokinetics of recombinant human granulocyte colony stimulating factor conjugated to polyethylene glycol in rats. Cancer Res. 51, 3710-3714.
180. Jensen-Pippo, K. E., Withcomb, K. L., DePrince, R. B., Ralph, L., and Habberfield, A. D. (1996) Enterai bioavailability of human granulocyte colony stimulating factor conjugated with poly(ethylene glycol). Pharmacol Res. 13, 102-107.
181. Yamasaki, M., Asano, M., Okabe, M., Morimoto, M., and Yokoo, Y. (1994) Modification of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and its derivative ND 28 with polyethylene glycol. J. Biochem. 115, 814-819.
182. Kitamura, K., Takahashi, T., Takashina, K., Yamaguchi, T., Noguchi, A., Tsurumi, H., Toyokumi, T., and Hakomori, S. (1990) Polyethylene glycol modification of the monoclonal antibody A7 enhances its tumor localization. Biochem. Biophys. Res. Commun. 171, 1387-1394.
183. Mast, A. E., Slvensen, G., Brucato, F. H., Schnebli, H. P., and Pizzo, S. V. (1990) Polyethylene glycol modification of Serpins improves therapeutic potential. Biol. Chem. Hoppe-Seyler 371 (Suppl.), 101-109.
184. Hershfield, M. S., Buckley, R. H., Greenberg, M. L., Melton, A. L., Schiff, R., Hatem, C., Kurtzberg, J., Matkert, M. L., Kobayashi, R. H., Kobayashi, A. L., and Abuchowski, A. (1987) Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N. Engl. J. Med. 316, 589-596.
185. Hershfield, M. S. (1997) Biochemistry and immunology of poly(ethylene glycol)-modified adenosine deaminase (PEGADA). In Poly(ethylene glycol): Chemistry and Biological Applications (J. M. Harris and S. Zalipsky, Eds.) pp 145-154, American Chemical Society, Washington, DC.
186. Fuertges, F., and Abuchowski, A. (1990) The clinical efficacy of poly(ethylene glycol)-modified proteins. J. Controlled Release 11, 139-148.
187. Ho, D. H., Wang, C. Y., Lin, J. R., Brown, N., Newman, R. A., and Krakoff, I. H. (1988) Polyethylene glycol-L-asparaginase and L-asparaginase studies in rabbits. Drug Metab. Dispos. 16, 27-29.
188. Park, Y. K., Abuchowski, A., Davis, S., and Davis, F. F. (1981) Pharmacology of Escherichia coli L-asparaginase polyethylene glycol adduct. Anticancer Res. 1, 373-376.
189. Abuchowski, A., Kazo, G. M., Verhoest, C. R., Jr., van Es, T., Kafkewitz, D., Nucci, M. L., Viau, A. T., and Davis, F. F. (1984) Cancer therapy with chemically modified enzymes I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem. Biophys. 7, 175-186.
190. Abuchowski, A., van Es, T., Palczuk, N. C., McCoy, J. R., and Davis, F. F. (1979) Treatment of L5178Y tumor-bearing BDF1 mice with a nonimmunogenic L-glutaminase-L-asparaginase. Cancer Treat. Rep. 63, 1127-1132.
191. Kamisaki, Y., Wada, H., Yagura, T., Nishimura, H., Matsushima, A., and Inada, Y. (1982) Increased antitumor activity of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol. Jpn. J. Cancer Res. 73, 470-474.
192. Jurgens, H., Schwamborn, D., Korholz, D., Wahn, V., and Gobel, U. (1988) Clinical experiences with polyethylene glycolbound E. coli L-asparaginase in patients with multiple recurrences of acute lymphoblastic leukemia. Klin. Pediatr. 200, 300-306.
193. Veronese, F. M., Monfardini, C., Caliceti, P., Schiavon, O., Scrawen, M. D., and Beer, D. (1996) Improvement of pharmacokinetic, immunological and stability properties of asparaginase by conjugation to linear and branched monomethoxy poly(ethylene glycol). J. Controlled Release 40, 199-209.
194. Cao, S. G., Zhao, Q., Ding, Z. T., Ma, L., Yu, T., Wang, J. H., Feng, Y., and Cheng, Y. H. (1990) Chemical modification of enzyme molecules to improve their characteristics. Ann. N.Y. Acad. Sci. 613, 460-467.
195. Abuchowski, A., Davis, F. F., and Davis, S. (1981) Immunosuppressive properties and circulating life of Achromobacter glutaminase-asparaginase covalently attached to polyethylene glycol in man. Cancer Treat. Rep. 65, 1077-1081.
196. Lisi, P. J., van Es, T., Abuchowski, A., Palczuk, N. C., and Davis, F. F. (1982) Enzyme therapy: polyethylene glycolglucuronidase conjugates as potential therapeutic agents in acid mucopolysaccharidosis. J. Appl. Biochem. 4, 19-33.
197. Cheng, R. H. L., Abuchowski, A., van Es, T., Palczuk, N. C., and Davis, F. F. (1981) Properties of two urate oxidases modified by the covalent attachment of polyethylene glycol. Biochim. Biophys. Acta 660, 293-298.
198. Newmark, J., Abuchowski, A., and Murano, G. (1982) Preparation and properties of adducts of streptokinase and streptokinase-plasmin complex with polyethylene glycol and pluronic polyol F38. J. Appl. Biochem. 4, 185-189.
199. Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T., and Davis, F. F. (1977) Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 252, 3582-3586.
200. Savoca, K. V., Abuchowski, A., van Es, T., Davis, F. F., and Paklczuk, N. C. (1979) Preparation of a non-immunogenic arginase by the covalent attachment of polyethylene glycol. Biochim. Biophys. Acta 578, 47-53.
201. Wieder, K. J., Palczuk, N. C., van Es, T., and Davis, F. F. (1979) Some properties of polyethylene glycol:phenylalanine ammonia-lyase adducts. J. Biol. Chem. 254, 12579-12587.
202. Kodera, Y., Sekine, T., Yasukohchi, T., Kiriu, Y., Hiroto, M., Matsushima, A., and Inada, Y. (1994) Stabilization of L-asparaginase modified with comb-shaped poly(ethylene glycol) derivatives, in vivo and in vitro. Bioconjugate Chem. 5, 283-286.
203. Sasaki, H., Ohtake, Y., Matsushima, A., Hiroto, M., Kodera, Y., and Inada, Y. (1993) Reduction of immunoreactivity of bovine serum albumin conjugated with comb-shaped polyethylene glycol derivatives. Biochem. Biophys. Res. Commun. 197, 287-291.
204. Boccu', E., Velo, G. P., and Veronese, F. M. (1982) Pharmacokinetic properties of polyethylene glycol derivatized superoxide dismutase. Pharmacol. Res. Commun. 14, 113-120.
205. Somack, R., Saifer, M. G. P., and Williams, L. D. (1991) Preparation of long-acting superoxide dismutase using high molecular weight polyethylene glycol (41,000-72,000 Daltons). Free Radical Res. Commun. 12-13, 553-562.
206. Saifer, M. G., Somack, R., and Williams, L. D. (1994) Plasma clearance and immunologic properties of long-acting superoxide dismutase prepared using 35,000 to 120,000 dalton poly-ethylene glycol. Adv. Exp. Med. Biol. 366, 377-387.
207. Nakaoka, R., Tabata, Y., Yamaoka, T., and Ikada, Y. (1997) Prolongation of the serum half-life period of superoxide dismutase by poly(ethylene glycol) modification. J. Controlled Release 46, 253-261.
208. Veronese, F. M., Caliceti, P., and Schiavon, O. (1997) Branched and linear poly(ethylene glycol): influence of the polymer structure on enzymological, pharmacokinetic, and immunological properties of protein conjugates. J. Bioact. Compat. Polym. 12, 196-207.
209. Sherman, M. R., Williams, L. D., Saifer, M. G. P., French, J. A., Kwak, L. W., and Oppenheim, J. J. (1997) Conjugation of high-molecular weight poly(ethylene glycol) to cytokines: granulocyte-macrophage colony-stimulating factors as model substrates. In Poly(ethylene glycol): Chemistry and Biological Applications (J. M. Harris and S. Zalipsky, Eds.) pp 155-169, American Chemical Society, Washington, DC.
210. Wada, H., Himamura, I., Sako, M., Katagiri, M., Tarui, S., Nishimura, H., and Inada, Y. (1990) Antitumor enzymes: polyethylene glycol-modified asparaginase. Ann. N.Y. Acad. Sci. 613, 95-108.
211. Koide, A., and Kobayashi, S. (1983) Modification of amino groups in porcine pancreatic elastase with polyethylene glycol in relation to binding activity towards anti-serum and to enzymatic activity. Biochem. Biophys. Res. Commun. 111, 659-667.
212. Abuchowski, A., and Davis, F. F. (1979) Preparation and properties of polyethylene glycol-trypsin adducts. Biochim., Biophys. Acta 578, 41-46.
213. Caliceti, P., Morpurgo, M., Schiavon, O., Monfardini, C., and Veronese, F. M. (1994) Preservation of thrombolytic activity of urokinase modified with monomethoxypoly(ethylene glycol). J. Bioact. Compat. Polym. 9, 252-266.
214. Caliceti, P., Schiavon, O., Sartore, L., Monfardini, C., and Veronese, F. M. (1993) Active site protection of proteolytic enzymes by poly(ethylene glycol) surface modification. J. Bioact. Compat. Polym. 8, 41-50.
215. Larionova, N. I., Gladysheva, I. P., Polekhina, O. V., and Garbatova, E. N. (1997) An ethylene oxide-propylene oxide block copolymer/Bowman-Birk proteinase inhibitor conjugate. Proc. Int. Symp. Controlled Release. Bioact. Mater., 24th, 491-492.
216. Noda, J., Otagiri, M., Akaike, T., and Maeda, H. (1996) Pharmacological advantages of conjugation of superoxide dismutase with succinylated keratin fragment. Proc. Int. Symp. Controlled Release Bioact. Mater., 23rd, 867-868.
217. Erhlich, P. (1956) A general review of the recent work in immunity. In Collected papers of Paul Erhlich, volume 2, Immunology and cancer research, pp 442-447, Pergamon Press, London.
218. Bernstein, A., Huewitz, E., Maron, R., Arnon, R., Sela, M., and Wilchek, M. (1978) Higher antitumor efficacy of daunomycin when linked to dextran: In vivo and in vitro studies. J. Natl. Cancer Inst. 60, 379-384.
219. Fujita, H., Okamoto, M., and Takao, A. (1991) Pharmacokinetics of adryamycin-oxidized dextran conjugate (ADMOXD) in experimental animals (in Japanese). Drug Delivery Syst. 6, 133-138.
220. Danhauser-Riedl, S., Hausamann, E., Schick, H. D., Bender, R., Dietzfelbinger, H., Rastetter, J., and Hanauske, A. R. (1993) Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest. New Drugs 11, 187-195.
221. Takakura, T., Kitajima, M., Matsumoto, S., Hashida, M., and Sezaki, H. (1987) Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with amonic charge. I. Physicochemical characteristics and in vivo and in vitro antitumor activities. Int. J. Pharm. 37, 135-143.
222. Coessens, V., Schacht, E. H., and Domurado, D. (1997) Synthesis and in vitro stability of macromolecular prodrugs of norfoxacin. J. Controlled Release 47, 283-291.
223. 99mTc-dextran and its accumulation with the inflammed paws of adjuvant-induced arthritic rats. Pharmacol. Res. 12, 588-593.
224. Duncan, R., Kopeckova-Rejmanova, P., Strohalm, J., Hume, I. C., Lloyd, J. B., and Kopecek, J. (1988) Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide co-polymers. 2. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia. Br. J. Cancer 57, 147-156.
225. Duncan, R., Seymour, L. W., O'Hare K. B., Flanagan, P. A., Wedge, S., Ulbrich, K., Strohalm, J., Subr, V., Spreafico, F., Grandi, M., Ripamonti, M., Farao, M., and Suarato, A. (1992) Preclinical evaluation of polymer-bound doxorubicin. J. Controlled Release 18, 123-132.
226. Duncan, R., Hume, I. C., Kopeckova, P., Ulbrich, K., Strohalm, J., and Kopecek, J. (1989) Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 3. Evaluation of adriamycin conjugates against mouse leukaemia L1210 in vivo. J. Controlled Release 10, 51-63.
227. O'Hare, K. B., Duncan, R., Strohalm, J., Ulbrich, K., and Kopeckova, P. (1993) Polymeric drug carriers containing doxorubicin and melanocyte-stimulating hormone: in vitro and in vivo evaluation against murine melanoma. J. Drug Targeting 1, 217-229.
228. Duncan, R., Hume, I. C., Yardley, H. J., Flanagan, P. A., Ulbrich, K., Subr, V., and Strohalm, J. (1991) Macromolecular prodrugs for use in targeted cancer chemotherapy: melphalan covalently coupled to N-(2-hydroxypropyl)methacrylamide copolymers. J. Controlled Release 16, 121-136.
229. Ulbrich, K., Zacharieva, E., Kopecek, J., Hume, I. C., and Duncan, R. (1987) Polymer bound derivatives of sarcolysin and their antitumor activity against mouse and human leukaemia in vitro. Makromol. Chem. 188, 2497-2509.
230. Krinick, N. L., Rihova, B., Ulbrich, K., Strohalm., J., and Kopecek, J. (1990) Targetable photoactive drugs 2. Synthesis of N-(2-hydroxypropyl)methacrylamide copolymer-anti-Thy-1.2 antibody-chlorin e6 conjugates and a preliminary study of their photodynamic effect on mouse splenocytes in vitro. Makromol. Chem. 191, 839-856.
231. Seymour, L. W., Flanagan, P. A., Al-Shamkhani, A., Subr, V., Ulbrich, K., Cassidy, J. A., and Duncan, R. (1991) Synthetic polymers conjugated to monoclonal antibodies: Vehicles for tumor-targeted drug delivery. Sel. Cancer Ther. 7, 59-73.
232. Duncan, R., Seymour, L. W., Scarlett, L., Lloyd, J. B., Rejmanova, P., and Kopecek, J. (1986) N-(2-Hydroxypropyl)-methacrylamide copolymers with pendant galactosamine residues. Fate after intravenous administartion to rats. Biochim. Biophys. Acta 880, 62-71.
233. Seymour, L. W., Ulbrich, K., Strahalm, J., Kopecek, J., and Duncan, R. (1990) Pharmacokinetics of polymer-bound adriamycin. Biochem. Pharmacol. 39, 1125-1131.
234. Merigan, T. C., and Regelson, W. (1967) Interferon induction in man by a synthetic polyanion of defined composition. N. Engl. J. Med. 277, 1283-1287.
235. Zalipski, S., Gilon, C., and Zilkgha, A. (1983) Attachment of drugs to polyethylene glycols. Eur. Polym. J. 19, 1177-1183.
236. Caliceti, P., Monfardini C., Sartore, L., Schiavon, O., Baccicchetti, F., Carlassare, F., and Veronese, F. M. (1993) Preparation and properties of monomethoxypoly(ethylene glycol) doxorubicin conjugates linked by an amnio acid or peptide as spacer. Farmaco 48, 919-932.
237. Ouchi, T., Yuyama, H., and Vogl, O. (1987) Synthesis of 5-fluorouracil-terminated monomethoxypoly(ethylene glycol)s, their hydrolysis behaviour, and their antitumor activities. J. Macromol. Sci. Chem. A24, 1011-1032.
238. Greenwald, R. B., Gilbert, C. W., Pendri, A., Conover, C. D., Xia, J., and Martinez, A. (1996) Drug-delivery systems: water soluble taxol 2′-poly(ethylene glycol) ester prodrugs-Design and in vivo effectiveness. J. Med. Chem. 39, 424-431.
239. Greenwald, R. B., Pendri, A., Conover, C., Gilbert, C., Yang, R., and Xia, J. (1996) Drug delivery systems. 2. Camptothecin 20-O-poly(ethylene glycol) ester transport forms. J. Med. Chem. 39, 1938-1940.
240. Poiani, G. J., Riley, D. J., Fox, J. D., Kemnizer, J. E., Gean, K. F., and Kohn, J. (1994) Conjugates of cis-4-hydroxy-L-proline and poly(PEG-Lys), a water soluble poly(ether urethane): synthesis and evaluation of antifibrotic effects in vitro and in vivo. Bioconjugate Chem. 5, 621-630.
241. Kwon, G., Suwa, S., Yokoyama, M., Okano, T., Sakurai, Y., and Kataoka, K. (1994) Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly(ethylene oxyde-aspartate) block copolymer-adryamicin conjugates. J. Controlled Release 29, 17-23.
242. Bogadnov, A. A., Jr., Callahan, R. J. Qwilkinson, R. A., Martin, C., Camero, J. A., Fischman, A. J., Brady, T. J., and Weissleder, R. (1994) Synthetic copolymer kit for radionuclide blood-pool imaging. J. Nucl. Med. 35, 1880-1886.
243. Fujii, K., Imai, T., and Otagiri, M. (1996) Control of pharmacokinetics and nefrotoxicity of cis-DDP by alginate. Proc. Int. Symp. Controlled Release Bioact. Mater., 23rd, 5018-5019.
244. Kato, Y., Liu, K., Nakamura, T., and Sugiyama, Y. (1996) Pharmocokinetic analysis of heparin-hepatocyte growth factor complex. Proc. Int. Symp. Controlled Release Bioact. Mater., 23rd, 647-648.
245. Zunino, F., Pratesi, G., and Pezzoni, G. (1987) Increased therapeutic efficacy and reduced toxicity of doxorubicin linked to pyran copolymer via the side-chain of the drug. Cancer Treat. Rep. 71, 367-373.
246. Bogliolo, G., Muzzulini, C., Lerza, R., and Pannacciulli, I. (1986) Activity of doxorubicin linked to poly-L-aspartic acid on normal murine hematopoietic progenitor cells. Cancer Treat. Rep. 70, 1275-1281.
247. Hrdina, R., Bogusova, T. A., Kunova, A., and Kvetina, J. (1991) Changes in the toxicity and therapeutic efficacy of daunorubicin linked with a biodegradable carrier. Neoplasma 38, 265-273.
248. Trouet, A., Masquelier, M., Baurain, R., and Campeneere, D. D. (1982) A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. Proc. Natl. Acad. Sci. U.S.A. 79, 626-629.
249. Decher, G., Emmelius, M., and Ringsdorf, H. (1984) Synthesis and antitumor activity of daunorubicin-containing polymers. In 26th Microsymposium on Polymers in Medicine and Biology, Prague, Czechoslovakia, pp 40-41.
250. Zunino, F., Savi, G., Giuliani, F., Gambetta, R., Supino, R., Tinelli, S., and Pezzoni, G. (1984) Comparison of antitumor effects of dounorubicin linked covalently to poly-L-amino acid carriers. Eur. J. Cancer Clin. Oncol. 20, 421-425.
251. Kery, V., Novotny, L., Tihlarik, K., Haplova, J., Kacurakova, M., Sandula, J., and Balazova, E. (1990) Preparation proparties and antileukaemic activity of arabinosylcytosine polysaccharide conjugates. Int. J. Biochem. 22, 1203-1207.
252. Ouchi, T., Fujino, A., Tanaka, K., and Banba, T. (1990) Synthesis and antitumor activity of conjugates of poly(α-malic acid) and 5-fluorouracils bound via ester, amide and carbamoyl bonds. J. Controlled Release 12, 143-153.
253. Chu, B. C. F., and Howell, S. B. (1981) Pharmacological and therapeutic properties of carrier bound methotrexate against tumor confined to a third space body compartment. J. Pharmacol. Exp. Ther. 219, 389-393.
254. Horpel, G., Klesse, W., and Ringsford, H. (1982) Micelle forming co- and block polymers for sustained drug release. IUPAC Proceedings of the International Symposium on Macromolecules, Amherst, MA, p 346.
255. Hirano, T., Ringsford, H., and Zaharko, D. (1980) Anti-tumor activity of monomeric and polymeric cyclophosphamide derivative compound with in vitro hydrolysis. Cancer Res. 40, 2263-2267.
256. Wu, G. Y., and Wu, C. H. (1988) Receptor-mediated gene delivery and expression in vivo. J. Biol. Chem. 263, 14621-14624.
257. Maruyama, A., Katoh, M., Ishihara, T., and Akaike, T. (1997) Comb-type polycations effectively stabilize DNA triplex. Bioconjugate Chem. 8, 3-6.
258. Bangham, A. D., and Horne, R. W. (1964) Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J. Mol. Biol. 8, 660-668.
259. Huang, C. (1969) Studies of phosphatidylcholine vesicles. Formation and physical characteristics. Biochemistry 8, 344-352.
260. Barenholtz, Y., Gibbes, D., Litman, B. J., Goll, J., Thompson, T. E., and Carlson, F. D. (1977) A simple method for the preparation of homogeneous phospholipid vesicles. Biochemistry 16, 2806-2810.
261. Batzri, S., and Korn, E. D. (1975) Interaction of phospho-lipid vesicles with cells. Endocytosis and fusion as alternative mechanisms for the uptake of lipid-soluble and water-soluble molecules. J. Cell. Biol. 66, 621-634.
262. Rolland, A., Ed. (1993) Pharmaceutical Particulate Carriers: Therapeutic Applications, Marcel Dekker, New York.
263. Gregoriadis, G., Ed. (1992) Liposome Technology, CRC Press, Boca Raton, FL.
264. Lopez-Berestein, G., and Fidler, I. J., Eds. (1989) Liposomes: the therapy of infectious diseases and cancer, Alan R. Liss, New York.
265. Roerdink, F. H., and Kroon, A. M., Eds. (1989) Drug Carrier Systems, Wiley & Sons, New York.
266. Gregoriadis, G., Ed. (1988) Liposomes as Drug Carriers: Recent Trends and Progress, Wiley & Sons, New York.
267. Machy, P., and Leserman, L., Eds. (1987) Liposomes in Cell Biology and Pharmacology, Wiley & Sons, London.
268. Ostro, M. J., Ed. (1987) Liposomes from Biophysics to Therapeutics, Dekker, New York.
269. Yagi, K., Ed. (1986) Medical Applications of Liposomes, Japan Scientific Society Press, Tokyo.
270. Gregoriadis, G., and Neerunjun, E. D. (1974) Control of the rate of hepatic uptake and catabolism of liposome-entrapped proteins injected into rat: possible therapeutic applications. Eur. J. Biochem. 47, 179-185.
271. Scherphof, G. L., Dikstra, J., Spanjer, H. H., Derksen, J. K., and Roerdink, T. (1985) Uptake and intracellular processing of targeted and nontargeted liposomes by rat Kupffer cells in vivo and in vitro. Ann. N.Y. Acad. Sci. 446, 368-384.
272. Alving, C. R., Steck, E. A., Chapman, W. L., Jr., Waits, V. B., Hendricks, L. D., Schwartz, G. M., Jr., and Hanson, W. L. (1978) Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proc. Natl. Acad. Sci. U.S.A. 75, 2959-2963.
273. Sone, S., Utsugi, T., Tandon, P., and Ogawara, M. A. (1986) A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the anticancer state. Cancer Immunol. Immunother. 22, 191-196.
274. Pak, R. R., and Fidler, I. J., (1991) Liposomal delivery of biological response modifiers to macrophages. Biotherapy 3, 55-64.
275. Hoekstra, D., and Scherphof, G. (1979) Effect of fetal calf serum protein fractions on the uptake of liposomal phosphatidylcholine by rat hepatocytes in primary monolayer. Biochim. Biophys. Acta 551, 109-121.
276. Rahman, A., More, N., and Schein, P. S. (1982) Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration. Cancer Res. 42, 1817-1825.
277. Van Hoesel, Q. G. C. M., Steerenberg, P. A., Crommelin, D. J. A., Van Dijk, A., Van Oort, W., Klein, S., Douze, J. M. C., De Wildt, D. J., and Hillen, F. C. (1984) Reduced cardiotoxicity and nephrotoxicity with preservation of anti-tumor activity of doxorubicin entrapped in stable liposomes in the LOU/M Ws1 rat. Cancer Res. 44, 3698-3705.
278. Lopez-Berestein, G. (1988) Liposomal amphotericin B in antimicrobial therapy. In Liposomes as Drug Carriers (G. Gregoriadis, Ed.), pp 345-352, Wiley & Sons, New York.
279. Lopez-Berestein, G., Fainstein, V., Hopfer, R., Mehta, K., Sullivan, M. P., Keating, M., Luna, M., Hersh, E. M., Reuben, J., Juliano, R. L., and Bodey, G. P. (1985) Liposomal amphotericin for the treatment of systemic fungal infections in patients with cancer. A preliminary study. J. Infect. Dis. 151, 704-710.
280. Lopez-Berestein, G., Bodey, G. P., Frankel, L. S., and Mehta, K. (1987) Treatment of hepato-splenic fungal infections with liposomal amphotericin B. J. Clin. Oncol. 5, 310-317.
281. Vasandani, V. M., Madan, S., and Ghosh, P. C. (1992) In vivo potentiation of ricin toxicity by monensin delivered through liposomes. Biochim. Biophys. Acta 1116, 315-323.
282. Burke, T. G., and Gao, X. (1994) Stabilization oftopotecan in low pH liposomes composed of distearylphosphatidylcholine. J. Pharm. Sci. 83, 967-968.
283. Chow, D. S. L., Chen, G., Gong, L., and Giovanella, B. C. (1997) Liposomal camptothecin and 9-nitro-camptothecin: formulation, pharmacokinetics and preclinical anti-tumor activity. Proc. Int. Symp. Controlled Release Bioact. Mater., 24th, 919-920.
284. Barzago, M. M., Bortolotti, A., Stellari, F. F., Diomede, L., Algeri, M., Efrati, S., Salmona, M., and Bonati, M. (1996) Placental transfer of valproic acid after liposome encapsulation during in vitro human placenta perfusion. J. Pharmacol. Exp. Ther. 277, 79-86.
285. Arien, A., Goigoux, C., Baquey, C., and Dupuy, B. (1993) Study of in vivo stability of oral liposomes loaded with calcitonin or indium in the gastrointestinal tract. Life Sci. 53, 1279-1290.
286. Arrowsmith, M., Hadgraft, J., and Kellaway, I. W. (1984) The in vivo release of cortisone esters from liposomes and the intramuscular clearance of liposomes. Int. J. Pharm. 20, 347-362.
287. Allen, T. M., Hansen, C. B., and Guo, L. S. S. (1993) Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochim. Biophys. Acta 1150, 9-16.
288. Lelkes, P. I., and Friedmann, P. (1984) Stabilization of large multilamellar liposomes by human serum in vitro. Biochim. Biophys. Acta 775, 395-401.
289. Senior, J. (1987) Fate and behaviour of liposomes in vivo: a review of controlling factors. Crit. Rev. Ther. Drug Carrier Syst. 3, 123-193.
290. Allen, T. M. (1981) A study of phospholipids interactions between high-density lipoproteins and small unilamellar vesicles. Biochim. Biophys. Acta 640, 385-397.
291. Senior, J., Gregoriadis, G., and Mitropoulos, K. (1983) Stability and clearance of small unilamellar liposomes: studies with normal and lipoprotein deficient mice. Biochim. Biophys. Acta 760, 111-118.
292. Patel, H. M., Tuzel, N. S., and Ryman, B. E. (1983) Inhibitory effect of cholesterol on the uptake of liposomes by liver and spleen. Biochim. Biophys. Acta 761, 142-151.
293. 14C]phosphatidylcholine between liposomes and human plasma high-density lipoproteins: partial purification of a transfer stimulating factor using a rapid transfer assay. Biochim. Biophys. Acta 712, 444-452.
294. Damen, J., Dijkstra, J., Regts, J., and Scherphof, G. L. (1980) Effect of lipoprotein-free plasma on the interaction of human plasma high-density lipoprotein with egg yolk phasphatidylcholine liposomes. Biochim. Biophys. Acta 620, 90-99.
295. Shahrokh, Z., and Nichols, A. V. (1982) Particle size interconversion of human low-density lipoproteins during incubation of plasma with phosphatidylcholine vesicles. Biochem. Biophys. Res. Commun. 108, 888-895.
296. Comiskey, S. J., and Heath, T. D. (1990) Serum-induced leakage of negatively charged liposomes at nanomolar lipid concentration. Biochemistry 29, 3626-3631.
297. Damen, J., Regts, J., and Scherphof, G. L. (1981) Transfer and exchange of phospholipid between small unilamellar liposomes and rat plasma high-density lipoproteins: dependence on cholesterol and phospholipid composition. Biochim. Biophys. Acta 665, 538-545.
298. Hunt, C. A. (1982) Liposomes disposition in vivo V. Liposomes stability in plasma and implications for drug carrier function. Biochim. Biophys. Acta 719, 450-463.
299. Senior, J., and Gregoriadis, G. (1982) Is half-life of circulating liposomes determined by changes in their permeability? FEBS Lett. 145, 109-114.
300. Bali, A., Dhawan, S., and Gupta, C. M. (1983) Stability of liposomes in circulation is markedly enhanced by structural modification of their phospholipid component. FEBS Lett. 154, 373-377.
301. Agarwal, K., Bali, A., and Gupta, C. M. (1986) Influence of the phospholipid structure in the stability of liposomes in serum. Biochim. Biophys. Acta 856, 36-40.
302. Patel, K. R., Li, M. P., Schuh, J. R., and Baldeschwielder, J. D. (1985) Modification of vesicles surface with amphiphilic sterols. Effect on permeability and in vivo tissue distribution. Biochim. Biophys. Acta 814, 256-264.
303. Oku, N., Namba, Y., and Okada, S. (1992) Tumor accumulation of novel RES-avoiding liposomes. Biochim. Biophys. Acta 1126, 255-260.
304. Kao, Y. J., and Juliano, R. L. (1981) Interactions of liposomes with the reticuloendothelial system: effects of reticuloendothelial blockade on the clearance of large unilamellar vesicles. Biochim. Biophys. Acta 677, 453-461.
305. 99mTc-labeled liposomes in patients with cancer. Cancer Res. 44, 375-378.
306. Poste, G., Bucana, C., Raz, A., Bugelski, P., Kiesh, R., and Fidler, I. J. (1982) Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res. 42, 1412-1422.
307. Spanier, H. H., Van Galen, M., Roerdink, F. H., Regts, J., and Scherphof, G. L. (1986) Intrahepatic distribution of small unilamellar liposomes as a function of liposomal lipid composition. Biochim. Biophys. Acta 863, 224-230.
308. Patel, H. M., Tuzel, N. S., and Ryman, B. E. (1983) Inhibitory effect of cholesterol on the uptake of liposomes by liver and spleen. Biochim. Biophys. Acta 761, 142-151.
309. Senior, J., Crawley, J. C. W., and Gregoriadis, G. (1985) Tissue distibution of liposomes exhibiting long half-lives in the circulation after intravenous injection. Biochim. Biophys. Acta 839, 1-8.
310. Nishikawa, K., Arai, H., and Inoue, K. (1990) Scavanger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages. J. Biol. Chem. 265, 5226-5231.
311. Tanaka, Y., and Schroit, A. J. (1983) Insertion of fluorescent phosphatidylserine into the plasma membrane of red blood cells: recognition by autologous macrophages. J. Biol. Chem. 258, 11335-11343.
312. Abra, R. M., Hunt, C. A., and Lau, D. T. (1984) Liposome disposition in vivo VI: delivery to the lung. J. Pharm. Sci. 73, 203-206.
313. Funato, K., Yoda, R., and Kiwada, H. (1992) Contribution of complement system on destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma. Biochim. Biophys. Acta 1103, 198-204.
314. Chonn, A., Semple, S. C., and Cullis, P. R. (1992) Association of blood proteins with large unilamellar liposomes in vivo. J. Biol. Chem. 267, 18759-18765.
315. Senior, J. H., Trimble, K. R., and Maskiewitz, R. (1991) Interaction of positively charged liposomes with blood: implications for their application in vivo. Biochim. Biophys. Acta 1070, 173-179.
316. Chow, D. D., Essien, H. E., Padki, M. M., and Hwang, K. J. (1989) Targeting small unilamellar liposomes to hepatic parenchymal cells by dose effect. J. Pharm. Exp. Ther. 248, 506-513.
317. Ogihara-Umeda, I., and Kojima, S. (1988) Increased delivery of gallium-67 to tumors using serum-stable liposomes. J. Nucl. Med. 29, 516-523.
318. Goto, M., Arakawa, M., Sato, T., Kondo, H., and Sunamoto, J. (1987) Specific rejection of glycophorin-reconstituted liposomes by human phagocytes. Chem. Lett. 2, 1935-1938.
319. Allen, T. M., and Chonn, A. (1987) Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett. 223, 42-46.
320. Gabizon, A., and Paphadjopoulos, D. (1988) Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. U.S.A. 85 6949-6953.
321. Allen, T. M., Hansen, C., and Rutledge, J. (1989) Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim. Biophys. Acta 981, 27-35.
322. Blume, G., and Cevc, G. (1990) Liposomes for the sustained drug release in vivo. Biochim. Biophys. Acta 1029, 91-97.
323. Allen, T. M., Hansen, G., Martin, F., Redeman, C., and Yau-Young, A. (1991) Liposomes containing synthetic lipid derivatives of poly(ethyleneglycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1066, 29-36.
324. Liu, D., Mori, A., and Huang, L. (1992) Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim. Biophys. Acta 1104, 95-101.
325. Yamauchi, H., Yano, T., Kato, T., Tanaka, I., Nakabayashi, S., Higashi, K., Miyoshi, S., and Yamada, H. (1994) Effects of sialic acid derivative on long circulating time and tumor concentration of liposomes. Int. J. Pharmacol. 113, 141-148.
326. 99mTc-labeled liposomal blood pool agents for nuclear medicine applications. Biochim. Biophys. Acta 1148, 77-84.
327. Yamauchi, H., Kikuchi, H., Yachi, K., Sawada, M., Tomikawa, M., and Hirota, S. (1993) Effects of glycophorin and ganglioside GM3 on the blood circulation and tissue distribution of liposomes in rats. Int. J. Pharmacol. 90, 73-79.
328. Allen, T. M., Austin, G. A., Chonn, A., Lin, L., and Lee, K. C. (1991) Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size. Biochim. Biophys. Acta 1061, 56-64.
329. Park, Y. S., Maruyama, K., and Huang, L. (1992) Some negatively charged phospholipid derivatives prolong the liposome circulation in vivo. Biochim. Biophys. Acta 1108, 257-260.
330. Namba, Y., Sakakibara, T., Masada, M., Ito, F., and Oku, N. (1990) Glucuronate-modified liposomes with prolonged circulation time. Chem. Pharm. Bull. 38, 1663-1666.
331. Woodle, M. C., Storm, G., Newman, M. S., Jekot, J. J., Collins, L. R., Martin, F. J., and Szoka, F. C., Jr. (1992) Prolonged systemic delivery of peptide drugs by long-circulating liposomes: illustration with vasopressin in the Brattlebor rat. Pharmacol. Res. 9, 260-265.
332. Namba, Y., Oku, N., Ito, F., Sakakibara, T., and Okada, S. (1992) Liposomal modification with uronate, which endows liposomes with long circulation in vivo, reduces the uptake of liposomes by J774 cells in vitro. Life Sci. 50, 1773-1779.
333. Juliano, R. L., Hsu, M. J., Regen, S. L., and Singh, M. (1984) Photopolymerized phospholipid vesicles: stability and retention of hydrophilic and hydrophobic marker substances. Biochim. Biophys. Acta 770, 109-114.
334. Juliano, R. L., Hsu, M. J., and Regen, S. L. (1985) Interaction of
335. Needham, D., McIntosh, T. J., and Lasic, D. D. (1992) Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. Biochim. Biophys. Acta 1108, 4-48.
336. Hoop, B., and Torchilin, V. P. (1996) Theoretical considerations on self-similarity of the polyethylene glycol-coated liposomal surface. Proc. Int. Symp. Controlled Release Bioact. Mater., 23rd, 785-786.
337. Klibanov, A. L., Maruyama, K., Beckerleg, A. M., Torchilin, V. P., and Huang, L. (1991) Activity of amphipathic poly-(ethylene glycol) 5,000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposomes binding to target. Biochim. Biophys. Acta 1062, 142-148.
338. Loughrey, H. C., Ferrarretto, A., Cannon, A. M., Acerbis, G., Sudati, F., Bottiroli, G., Masserini, M., and Soria, M. R. (1993) Characterization of biotinylated liposomes for in vivo targeting applications. FEBS Lett. 332, 183-188.
339. Torchilin, V. P., Omelyanenko, V. G., Papisov, M. I., Bogdanov, A. A., Trubetskoy, V. S., Herron, J. N., and Gentry, C. A. (1994) Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposomes longevity. Biochim. Biophys. Acta 1195, 11-20.
340. Blume, G., and Cevc, G. (1993) Molecular mechanism of the lipid vesicle longevity in vivo. Biochim. Biophys. Acta 1146, 157-168.
341. Parr, M. J., Ansell, S. M., Lewis, S. C., and Cullis, P. R. (1994) Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles. Biochim. Biophys. Acta 1195, 21-30.
342. Maruyama, K., Yuda, T., Okamoto, A., Kojima, S., Suginaka A., and Iwatsuru, M. (1992) Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoylphosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). Biochim. Biophys. Acta 1128, 44-49.
343. Litzinger, D. C., Buiting, A. M. J., van Rooijen, N., and Huang, L. (1994) Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim. Biophys. Acta 1190, 99-107.
344. Yuda, T., Maruyama, K., and Iwatsuru, M. (1996) Prolongation of liposome circulation time by various derivatives of polyethylene glycols. Biol. Pharm. Bull. 19, 1347-1351.
345. Torchilin, V. P., Trubetskoy, V. S., Whiteman, K. R., Caliceti, P., Ferruti, P., and Veronese, F. M. (1995) New synthetic amphiphilic polymers for steric protection of liposomes in vivo. J. Pharm. Sci. 84, 1049-1053.
346. Takeuchi, H., Toyoda, T., Toyobuku, H., Yamamoto, H., Hino, T., and Kawashima, Y. (1996) Improved stability of doxorubicin-loaded liposomes by polymer coating. Proc. Int. Symp. Controlled Release Bioact. Mater., 23rd, 409-410.
347. Takeuchi, H., Yamamoto, H., Niwa, T., Hino, T. and Kawashima, Y. (1994) Mucoadhesion of polymer-coated liposomes to rat intestine in vitro. Chem. Pharm. Bull. 42, 1954-1956.
348. Takeuchi, H., Yamamoto, H., Niwa, T., Hino, T., and Kawashima, Y. (1996) Enterai absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm. Res. 13, 896-901.
349. Maruyama, K., Okuizumi, S., Ishida, O., Yamauchi, H., Kikuchi, H., and Iwatsuru, M. (1994) Phosphatidylpolyglycerols prolong liposome circulation in vivo. Int. J. Pharm. 111, 103-107.
350. Woodle, M. C., Engbers, C. M., and Zalipsky, S. (1994) New amphipathic polymer-lipid conjugates forming long-circulating reticuloendothelial system-evading liposomes. Bioconjugate Chem. 5, 493-496.
351. Kang, E. C., Akiyoshi, K., and Sunamoto, J. (1997) Surface coating of liposomes with hydrophobized polysaccharides. J. Bioact. Compat. Polym. 12, 14-26.
352. Gregoriadis, G., McCormack, B., Wang, Z., and Lifely, R. (1993) Polysialic acids: potential in drug delivery. FEBS Lett. 315, 271-276.
353. Zhang, X., and Gregoriadis, G. (1997) Polysialylated liposomes: preparation and fate in vivo. Proc. Int. Symp. Controlled Release Bioact. Mater., 24th, 861-862.
354. van Rooijen, N., Bakekr, J., and Sander, A. (1997) Transient suppression of macrophage function by liposomes-encapsulated drugs. Trends Biotechnol. 15, 178-185.
355. Kennel, S. J., Lankford, T., Hughes, B., and Hotchkiss, J. (1988) Quantitation of a murine lung endothelial cell protein, p112, with a double monoclonal antibody assay. Lab. Invest. 59, 692-701.
356. Maruyama, K., Kennel, S., and Huang, L. (1990) Lipid composition is important for highly efficient target binding and retention of immunoliposomes. Proc. Natl. Acad. Sci. U.S.A. 87, 5744-5748.
357. Mori, A., Klibanov, A. L., Torchilin, V. P., and Huang, L. (1991) Influence of the steric barrier activity of amphipathic poly(ethylene glycol) and ganglioside GM1 on the circulation time of liposomes and the target binding of immunoliposomes in vivo. FEBS Lett. 284, 263-266.
358. Holmberg, E., Maruyama, K., Litzinger, D., Wright, S., Davis, M., Kabalka, G. W., Kennel, S. J., and Huang, L. (1989) Highly efficient immunoliposomes prepared with a method which is compatible with various lipid compositions. Biochem. Biophys. Res. Commun. 165, 1272-1278.
359. Emanuel, N., Kedar, E., Bolotin, E. M., Smorodinsky, N. I., and Barenholz, Y. (1996) Preparation and characterization of doxorubicin-loaded sterically stabilized immunoliposomes. Pharm. Res. 13, 352-359.
360. Blume, G., Cevc, G., Crommelin, M. D., Bakker-Woundenberg, I. A., Kluft, C., and Storm. G. (1993) Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim. Biophys. Acta 1149, 180-184.
361. Zalipsky, S., Mullah, N., Harding, J. A., Gittelma, J., Guo, L., and DeFrees, S. A. (1997) Poly(ethylene glycol)-grafted liposomes with oligopeptide or oligosaccharide ligands appended to the termini of the polymer chains. Bioconjugate Chem. 8, 111-118.
362. Yoshikawa, Y., Miyazaki, M., Houjou, T., Komuta, Y., Yoshikawa, H., and Takada, K. (1997) Biodistribution of cyclosporin encapsualted in liposomes modified with bioadhesive polymer. J. Pharm. Pharmacol. 49, 661-668.
363. Maruyama, K., Unezaki, S., Takahashi, N., and Iwatsuru, M. (1993) Enhanced delivery of doxorubicin to tumor by long circulating thermosensitive liposomes and local hyperthermia. Biochim. Biophys. Acta 1149, 209-216.
364. Huang, S. K., Stauffer, P. R., Hong, K., Guo, J. W. H., Phillips, T. L., Huang, A., and Papahadjopoulos, D. (1994) Liposomes and hyperthemia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res. 54, 2186-2191.
365. Unezaki, S., Maruyama, K., Takahashi, N., Koyama, M., Yuda, T., Suginaka, A., and Iwatsuru, M. (1994) Enhanced delivery and antitumor activity of doxorubicin using long-circulating thermosensitive liposomes containing amphipathic polyethylene glycol in combination with local hyperthermia. Pharm. Res. 11, 1180-1185.
366. Masuko, Y., Tazawa, K., Sato, H., Viroonchatapan, E., Takemori, S., Shimizu, T., Ohkami, H., Nagae, H., Fujimaki, M., Horikoshi, I., and Weinstein, J. N. (1997) Antitumor activity of selective hyperthermia in tumor-bearing rats using thermosensitive magnetoliposomes as a new hyperthermic material. Drug Delivery 4, 37-42.
367. Connor, J., Yatvin, M. B., and Huang, L. (1984) pH-sensitive liposomes: acid-induced liposomes fusion. Proc. Natl. Acad. Sci. U.S.A. 81, 1715-1718.
368. Connor, J., and Huang, L. (1986) pH-sensitive immunoliposomes as an efficient and target-specific carrier for antitumor drugs. Cancer Res. 46, 3431-3435.
369. Oku, N., Shibamoto, S., Ito, F., Gondo, H., and Nango, M. (1987) Low pH induced membrane fusion of lipid vesicles containing proton-sensitive polymer. Biochemistry 26, 8145-8150.
370. Ho, R. J. Y., Rouse, B. T., and Huang, L. (1986) Target-sensitive immunoliposomes: preparation and characterization. Biochemistry 25, 5500-5506.
371. Ho, R. J. Y., Rouse, B. T., and Huang, L. (1987) Target-sensitive immunoliposomes as an efficient drug carrier for antiviral activity. J. Biol. Chem. 262, 13973-13978.
372. Slepushkin, V. A., Simoes, S., Dazin, P., Newman, M. S., Guo, L. S., Pedroso de Lima, M. C., and Duzgunes, N. (1997) Sterically stabilized pH-sensitive liposomes. J. Biol. Chem. 272, 2382-2388.
373. Hong, M. S., and Kim, C. K. (1996) Preparation and evaluation of pH-sensitive long-circulating liposomes entrapped methotrexate. Proc. Int. Symp. Controlled Release Bioact. Mater., 23rd, 923-924.
374. Deverre, J. R., Bouteet, V., de Oliveira, M. C., Fattal, E., Boquet, D., Grogne, J. M., and Couvreur, P. (1997) Plasma stability and pharmacokinetic profile of phosphodiester antisense oligonucleotide encapsulated in pH sensitive liposomes. Proc. Int. Symp. Controlled Release Bioact. Mater., 24th, 663-664.
375. Couveur, P., Fattal, E., Malvy, C., and Dubernet, C. (1997) pH-sensitive liposomes: an intelligent system for the delivery of antisense oligonucleotides. J. Liposome Res. 7, 1-18.
376. Gabizon, A., Prince, D. C., Huberty, J., Bresalier, R. S., and Papahadjopoulos, D. (1990) Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res. 50, 6371-6378.
377. 67Gallium-labeled liposomes with prolonged circulation: preparation and potential as nuclear imaging agents. Nucl. Med. Biol. 20, 149-155.
378. Oku, N., Namba, Y., Takeda, A., and Okada, S. (1993) Tumor imaging with technetium-99m-DTPA encapsulated in RES-avoiding liposomes. Nucl. Med. Biol. 20, 407-412.
379. Gabizon, A. (1992) Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 52, 891-896.
380. Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, K., Lee, K. D., Woodle, M. C., Lasic, D. D., Redemann, C., and Martin, F. J. (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. U.S.A. 88, 11460-11464.
381. Huang, S. K., Nayhew, E., Gilani, S., Lasic, D. D., Martin, F. J., and Papahadjopoulos, D. (1992) Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 52, 6774-6781.
382. Oku, N., Doi, K., Namba, Y., and Okada, S. (1994) Therapeutic effect of adriamycin encapsulated in long-circulating liposomes on Meth-A-sarcoma-bearing mice. Int. J. Cancer 58, 415-419.
383. Vaage, J., Mayhew, E., Lasic, D., and Martin, F. (1992) Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. Int. J. Cancer 51, 942-948.
384. Vaage, J., Donovan, D., Loftus, T., Abra, R., Working, P., and Huang, A. (1994) Chemoprevention and therapy of mouse mammary carcinomas with doxorubicin encapsulated in sterically stabilized liposomes. Cancer 73, 2366-2371.
385. Vaage, J., Donovan, D., Mayhew, E., Abra, R., and Huang, A. (1993) Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 72, 3671-3675.
386. Vaage, J., Barbera-Guillem, E., Abra, R., Huang, A., and Working, P. (1994) Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 73, 1478-1484.
387. Huang, S. C., Lee, K. D., Friend, D. S., and Papahadjopoulos, D. (1992) Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 52, 5135-5143.
388. Puisiex, F., Barrat, G., Courraze, G., Couvreur, P., Devissaguet, J. P., Dubernet, C., Fattal, E., Fessi, H., Vauthier, C., and Benita, S. (1994) Polymeric micro- and nanoparticles as drug carriers. In Polymeric Biomaterials (S. Dumitriu, Ed.) pp 749-794, Marcel Dekker, New York.
389. Dakhil, S., Ensminger, W., Cho, K., Neiderhuber, J., Doan, K., and Wheeler, R. (1982) Improved regional selectivity of hepatic arterial BCNU with degradable microspheres. Cancer 50, 631-635.
390. Gupta, P. K. (1990) Drug targeting in cancer chemotherapy: a clinical perspective. J. Pharm. Sci. 79, 949-962.
391. Flandroy, P., Grandfils, C., Colligon, J., Thibaut, A., Nihant, N., Barbette, S., Jerome, R., and Teyssie, P. (1990) D,L-Polylactide microspheres as embolic agent. A preliminary study. Neuroradiology 32, 311-315.
392. Kato, T., Nemoto, R., Mori, H., Takahashi, M., and Tamakawa, Y. (1981) Transcatheter arterial chemoembolization of renal cell carcinoma with microencapsulated mitomycin C. J. Urol. 125, 19-24.
393. Nemoto, R., Kato, T., Iwata, K., Mori, H., and Takahashi, M. (1981) Evaluation of therapeutic arterial embolization in renal cell carcinoma using microencapsulated mitomycin C. Urology 17, 315-319.
394. Pinski, J., Reile, H., Halmos, G., Groot, K., and Schally, A. V. (1994) Inhibitory effect of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Cancer Res. 54, 169-174.
395. Yano, T., Pinski, J., Szepeshazi, K., Milovanovic, S. R., Groot, K., and Schally, A. V. (1992) Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analogue RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model. Prostate 20, 297-310.
396. Cleland, J. L., Mac, A., Boyd, B., Yang, J., Duenas, E. T., Yeung, D., Brooks, D., Hsu, C., Chu, H., Mukku, V., and Jones, A. J. S. (1997) The stability of recombinant human growth hormone in poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm. Res. 14, 420-425.
397. Singh, U. V., Udupa, N., Kamath, R., and Umadevi, P. (1997) Enhanced antitumor efficacy of methotrexate poly-(lactic-co-glycolic) acid injectable gel implants in mice bearing sarcoma-180. Pharm. Sci. 3, 133-136.
398. Blanco-Prieto, M. J., Orsolini, P., Heimgartner, F., Besseghir, K., Merkle, H. P., and Gander, B. (1997) In vitro and in vivo release kinetics of a somatostatin analogue from PLGA microspheres. Proc. Int. Symp. Controlled Release Bioact. Mater., 24th, 953-954.
399. Kissel, T., Li, Y. X., Volland, C., Gorich, S., and Koneberg, R. (1996) Parental protein delivery systems using biodegradable polyesters of ABA block structure, containing hydrophobic poly(lactide-co-glycolide) A blocks and hydrophilic poly-(ethylene oxide) B blocks. J. Controlled Release 39, 315-326.
400. Coombes, A. G. A., Tasker, S., Lindblad, M., Holmgren, J., Hoste, K., Toncheva, V., Schacht, E., Davies, M. C., Illum, L., and Davis, S. S. (1997) Biodegradable polymeric microparticles for drug delivery and vaccine formulation: the surface attachment of hydrophilic species using the concept of poly(ethylene glycol) anchoring segments. Biomaterials 18, 1153-1161.
401. Inoue, T., Nawa, Y., Tsutsumiuchi, R., Imaeda, M., Matsuda, H., and Ueda, Y. (1997) A novel lipid microsphere emulsified by lecithin with saturated fatty acids for prolonged parental drug delivery. Proc. Int. Symp. Controlled Release Bioact. Mater., 24th, 983-984.
402. Couvreur, P., Roland, M., and Speiser, P. (1982) Biodegradable submicroscopic particles containing a biologically active substance and compositions containing them. U.S. Patent 4,329,332.
403. Alkouri-Fallouh, N., Roblot-Treupel, L., Fessi, H., Devissaguet, J. P., and Puisieux, F. (1986) Development of a new process for the manufacture of polyisobutylcyanoacrylate nanocapsules. Int. J. Pharmacol. 28, 125-132.
404. Rollot, J. M., Couvreur, P., Roblot-Treupel, L., and Puisieux, F. (1986) Physicochemical and morphological characterization of polyisobutylcyanoacrylate nanocapsules. J. Pharm. Sci. 75, 133-165.
405. Gurny, R., Peppas, N. A., Harrington, D. D., and Banker, G. S. (1981) Development of biodegradable and injectable latices for controlled release of potent drugs. Drug. Dev. Ind. Pharm. 7, 1-25.
406. Krause, H. J., Schwartz, A., and Rohdelwald, P. (1985) Polylactic acid nanoparticles, a colloidal drug delivery system for lipophilic drugs. Int. J. Pharm. 27, 145-155.
407. Kramer, P. A. (1974) Albumin microspheres as vehicles for achieving specificity in drug delivery. J. Pharm. Sci. 63, 1646-1647.
408. Fessi, H., Devissaguet, J. P., Puisieux, F., and Thies, C. (1986) Procede de preparation des systemes colloidaux dispersibles d'une substance sous forme de nanocapsules (Procedure for the preparation of dispersable colloidal systems of a substance in the form of nanocapsules). Fr. Pat. Appl. 8,-618,446.
409. Marty, J. J., Oppenheim, R. C., and Speiser, P. (1978) Nanoparticles: a new colloidal drug delivery system. Pharm. Acta Helv. 53, 17-22.
410. Stainmesse, S., Fessi, H., Devissaguet, J. P., and Puisieux, F. (1988) Procede de preparation des systemes colloidaux dispersibles d'une protein sous forme de nanoparticles (Procedure for the preparation of dispersable colloidal systems of a protein in the form of nanoparticles). First Addition to Fr. Pat. Appl. 8,618,446.
411. Sterling, C. V., and Scriven, L. E. (1959) Interfacial turbulence: hydrodynamic instability and Marangoni effect. AIChE J. 5, 514-523.
412. Fessi, H., Devissaguet, J. P., and Puisieux F. (1986) Procede de preparation des systemes colloidaux dispersibles d'une substance sous forme de nanocapsules (Procedure for the preparation of dispersable colloidal systems of a substance in the form of nanocapsules). Fr. Pat. Appl. 8,618,444.
413. Quintanar-Guerrero, D., Fessi, H., Allemann, E., and Doelker, E. (1996) Influence of stabilizing agents and preparative variables on the formation of poly(D,L-lactic acid) nanoparticles by an emulsification-diffusion technique. Int. J. Pharm. 143, 133-141.
414. Couvreur, P., Kante, B., Grislain, L., Roland M., and Speiser, P. (1982) Toxicity of polyalkyl-cyanoacrylate nanoparticles. II. Doxorubicin-loaded nanoparticles. J. Pharm. Sci. 71, 790-792.
415. Verdun, C., Brasseur, F., Vranckx, H., Couvreur, P., and Roland, M. (1990) Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles. Cancer Chemother. Pharmacol. 26, 13-18.
416. Chiannilkulchai, N., Driouich, Z., Benoit, J. P. Parodi, A. L., and Couvreur, P. (1990) Doxorubucin loaded nanoparticles: increased efficiency in murine hepatic metastases. Sel. Cancer Ther. 5, 1-11.
417. Barrat, G. M., Yu, W. P., Fessi, H., Devissaguet J. P., Puisieux, F., Petit, J. F., Tenu, J. P., Israel, L., and Morere, J. F. (1989) Delivery of MDP-L-alanyl-cholesterol to macrophages: comparison of liposomes and nanocapsules. Cancer J. 2, 439-443.
418. Wilkins, D. J., and Myers, P. A. (1966) Studies on the relationship between the electrophoretic properties of colloids and their blood clearance and organ distribution in the rat. Br. J. Exp. Pathol. 47, 568-576.
419. 14C-labeled amino-modified polystyrene nanoparticles in mice. J. Pharm. Sci. 84, 1249-1253.
420. Illum, L., Davis, S. S., Muller, R. H., Mak, E., and West, P. (1987) The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer-poloxamine 908. Life Sci. 40, 367-374.
421. Moghimi, S. M., Hedeman, H., Muir, I. S., Illum, L., and Davis, S. S. (1993) An investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen. Biochim. Biophys. Acta 1157, 233-240.
422. Moghimi, S. M., Porter, C. J. H., Muir, I. S., Illum, L., and Davis, S. S. (1991) Non-phagocitic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. Biochem. Biophys. Res. Commun. 177, 861-866.
423. Porter, C. J. H., Moghimi, S. M., Illum, L., and Davis S. S. (1992) The polyoxyethylene/polyoxypropylene block copolymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Lett. 305, 62-67.
424. Moghimi, S. M., Hedeman, H., Christy, N. M., Illum, L., and Davis, S. S. (1993) Enhanced hepatic clearance of intravenously administered sterically stabilized microspheres in zymosan-stimulated rats. J. Leukocyte Biol 54, 513-517.
425. Illum, L., Jacobsen, L. O., Muller, R. H., Mak, E., and Davis, S. S. (1987) Surface characteristics and the interaction of colloidal particles with mouse peritoneal macrophages. Biomaterials 8, 113-117.
426. Van Oss, C. F., Gillman, C. F., and Neuman, A. W., Eds. (1975) Phagocytic engulfment and cell adhesiveness, Marcel Dekker, New York.
427. Moghimi, S. M., and Patel, H. M. (1989) Differential properties of organ-specific serum opsonins for liver and spleen macrophages. Biochim. Biophys. Acta 984, 379-383.
428. Patel, H. M. (1992) Serum opsonins and liposomes: their interaction and opsonophagocytosis. Crit. Rev. Ther. Drug Carrier Syst. 9, 39-90.
429. Kolb-Bachofen, V., and Abel, F. (1991) Participation of D-galactose-specific receptors of liver macrophages in recognition of fibronectin-opsonized particles. Carbohydr. Res. 213, 201-213.
430. Ulrich, F., and Meier, F. M. (1973) Inhibition of phagocytosis: effect of normal rabbit serum on E. coli uptake by rabbit alveolar macrophages. J. Reticuloendothel. Soc. 14, 8-17.
431. Moghimi, S. M., and Patel, H. M. (1989) Serum opsonins and phagocytosis of saturated and unsaturated phospholipid liposomes. Biochim. Biophys. Acta 984, 384-387.
432. Nicholas, A. R., and Jones, N. M. (1991) The effect of blood on the uptake of liposomal lipid by perfused rat. Biochim. Biophys. Acta 1074, 105-111.
433. Moghimi, S. M., Muir, I. S., Illum, L., Davis, S. S., and Kolb-Bachofen, V. (1993) Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim. Biophys. Acta 1179, 157-165.
434. Kolb-Bachofen, V., Schlepper-Schafer, J., Vogell, W., and Kolb, H. (1982) Electron microscopic evidence for an asialoglycoprotein receptor on Kupffer cells: localization of lectin-mediated endocytosis. Cell 29, 859-866.
435. Kolb-Bachofen, V. (1992) Uptake of toxic silica particles by isolated rat liver macrophages (Kupffer cells) is receptor mediated and can be blocked by competition. J. Clin. Invest. 90, 1819-1824.
436. Stolnik, S., Dunn, S. E., Garnett, M. C., Davies, M. C., Coombes, A. G. A., Taylor, D. C., Irving, M. P., Purkiss, S. C., Tadros, T. F., Davis, S. S., and Illum, L. (1994) Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers. Pharmacol. Res. 11, 1800-1808.
437. Hawley, A. E., Illum, L., and Davis, S. S. (1997) Preparation of biodegradable, surface engineered PLGA nanospheres with enhanced lymphatic drainage and lymph node uptake. Pharm. Res. 14, 657-661.
438. Peracchia, M. T., Desmaele, D., Appel, M., d'Angelo, J., and Couvreur P. (1997) PEG-coated nanoparticles from a novel poly(MePEG cyanoacrylate-co-alkyl cyanoacrylate) amphiphilic copolymer. Proc. Int. Symp. Controlled Release Bioact. Mater., 24th, 124-125.
439. Peracchia, M. T., Vauthier, C., Puisieux, F. and Couvreur, P. (1996) PEG-PIBCA nanoparticles with different PEG-coating configurations formed by chemical coupling of PEG. Proc. Int. Symp. Controlled Release Bioact. Mater., 23rd, 395-396.
440. Vandorpe, J., Schacht, E., Dunn, S., Hawley, A., Stolnik, S., Davis, S. S., Garnett, M. C., Davies, M. C., and Illum, L. (1997) Long circulating biodegradable poly(phosphazene) nanoparticles surface modified with poly(phosphazene)-poly-(ethyleneoxide) copolymer. Biomaterials 18, 1147-1152.
441. Hansrani, P. K., Davis, S. S., and Groves, M. J. (1983) The preparation and properties of sterile intravenous emulsions. J. Parenter. Sci. Technol. 37, 145-150.
442. Hisaoka, M., Kurihara, A., Kasuya, A., and Ikeda, M. (1997) Pharmacokinetics of highly lipophilic antitumor agents incorporated in lipid emulsions. Proc. Int. Symp. Controlled Release Bioact. Mater., 24th, 1049-1050.
443. Singh, M., and Ravin, L. J. (1986) Parental emulsions as drug carrier system. J. Parenter. Sci. Technol. 40, 34-41.
444. Poste, G., Bucana, C., Raz, A., Bugelski, P., Kirsh, R., and Fidler, I. J. (1982) Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res. 42, 1412-1422.
445. Sonoke, S., Saheki, A., Yoshikawa, H., Nagata T., Fukui, H., and Seki, J. (1996) Apolipoprotein E plays a key role in the hepatic clearance of exogenous lipid emulsions. Proc. Int. Symp. Controlled Release Bioact. Mater., 23rd, 667-668.
446. Liu, F., and Liu, D. (1995) Long-circulating emulsions (oil-in-water) as carriers for lipophilic drugs. Pharmacol. Res. 12, 1060-1064.
447. Lundberg, B. (1997) A submicron lipid emulsion coated with amphipathic polyethylene glycol for parental administration of Paclitaxel (Taxol). J. Pharm. Pharmacol. 49, 16-21.
448. Kwon, G. S., Yokoyama, M., Okano, T., Sakurai, Y., and Kataoka, K. (1993) Biodistribution of micelles forming polymer-drug conjugates. Pharmacol. Res. 10, 970-974.
449. Chiu, H. C., Chern, C. S., Lee, C. K., and Chang, H. F. (1996) Synthesis and characterization of poly(ethylene glycol) derived comb copolymers. Proc. Int. Symp. Controlled Release Bioact. Mater., 23rd, 757-758.
450. Nagasaki, Y., Scholz, C., Iijma, M., Kato, M., and Kataoka K. (1996) A novel reactive polymeric micelles for an intelligent drug carrier. Proc. Int. Symp. Controlled Release Bioact. Mater., 23rd, 779-780.
451. Trubetskoy, V. S., Frank-Kamenetsky, M. D., Whiteman, K. R., Wolf, G. L., and Torchilin, V. P. (1996) Stable polymeric micelles: lymphangiographic contrast media for gamma scintigraphy and magnetic resonance imaging. Acad. Radiol. 3, 232-238.
452. Torchilin, V. P. (1997) Pharmacokinetic considerations in the development of labeled liposomes and micelles for diagnostic imaging. Q. J. Nucl. Med. 41, 141-153.
453. Takakura, Y., Mihara, K., and Hashida, M. (1994) Control of the disposition profiles of proteins in the kidney via chemical modification. J. Controlled Release 28, 111-119.
454. Marbach, P., Briner, U., Lemaire, M., Schweitzer, A. and Terasaki, T. (1993) From somatostatin to sandostatin: pharmacodynamics and pharmacokinetics. Digestion 54, 9-13.
455. Baldwin, R. W., Byers, V. S., and Mann, R. D., Eds. (1990) Monoclonal antibodies and immunoconjugates, Partheneon, Carnforth, U.K.
456. Winter, G., and Miolstein, C. (1991) Man-made antibodies. Nature 349, 293-299.
457. Glockshuber, R., Malia, M., Pfitzinger, I., and Pluckthum, A. (1990) A comparison of strategies to stalibilize immunoglobulin Fv fragments. Biochemistry 29, 1362-1367.
458. Cumber, A. J., Ward, E. S., Winter, G., Parnell, G. D., and Wawrzynczak, J. (1992) Comparative stabilities in vitro and in vivo of a recombinant mouse antibody FvCys fragment and a bisFvCys conjugate. J. Immunol. 149, 120-126
459. Yokota, T., Milenic, D. E., Withlow, M., and Scholm, J. (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52, 3402-3408.
460. Reiter, Y., Pai, L. H., Brinkmann, U. Wang, Q., and Pastan, I. (1994) Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Cancer Res. 54, 2714-2718.
461. Gartshore, G., Bannan, P., Patterson, J., Highley, B., and McCulloch, J. (1994) Evaluation of technetium-99m exametazime stabilised with cobalt chloride as a blood flow tacer in focal cerebral ischemia. Eur. J. Nucl. Med. 21, 913-923.
462. 99mTc-HPMAO): basic kinetic studies of a tracer of cerebral blood flow. Cerebrovasc. Brain Metab. Rev. 1, 288-318.
463. Peters, A. M., Osman, S., Henderson, B. L., Kelly, J. D., Danrupe, H. J., Hawker, R. J., Hodgson, H. J., Neirinckx, R. D., and Lavender, J. P. (1986) Clinical experience with Tc-99m-HPMAO for labeling leucocytes and imaging inflammation. Lancet 2, 926-949.
464. 99m-Tc-hexamethylpropylene amine oxime SPECT and X-ray CT in acute cerebral ischemia. J. Neurol. 237, 475-479.
465. Sharp, P. F., Smith, F. W., Gemmell, H. G., Lyall, D., Evans, N. T. S., Gvozdanovic, D., Davidson, J., Tyrrell, D. A., Pickett, R. D., and Neirinckx, R. D. (1986) Technetium-99m HM-PAO stereisomers as potential agents for imaging regional cerebral blood flow: human volunteer studies. J. Nucl. Med. 27, 171-177.
466. Igarashi, R., Hoshino, J., Ochiai, A., Morizawa, Y., and Mizushima, Y. (1994) Lecithinized superoxide dismutase enhances its pharmacologic potency by increasing its cell membrane affinity. J. Pharmacol. Exp. Ther. 271, 1672-1677.
467. Igarashi, R., Tsutsumi, Y., Fujii, H., Tsunoda, S., Ochiai, A., Takenaga, M., Morizawa, Y., Mayumi, T., and Mizushima, Y. (1997) Lecithinization of IL-6 enhances its thrombopoietic activity in mice. J. Pharm. Pharmacol. 49, 113-118.
468. Todoya, E., Uemura, K., Tenma, T., Fujita, T., Murakami, M., Yamamoto, A., and Muranishi, S. (1994) Enhanced permeability of tetragastrin across the rat intestinal membrane and its reduced degradation by acylation with various fatty acids. J. Pharmacol. Exp. Ther. 271, 1509-1513.
469. Honeycutt, L. R., Wang, J., Ekrami, H., and Shen, W. C. (1996) Comparison of pharmacokinetic parameters of a polypeptide, the Bowman-Birk protease inhibitor (BBI), and its palmitic acid conjugate. Pharm. Res. 13, 1373-1377.
470. Shen, W. C., Wang, J., and Shen, D. (1997) Reversible lipidization of polypeptides in drug delivery. Proc. Int. Symp. Controlled Release Bioact. Mater., 24th, 202-203.
471. Trotta, M., Pattarino, F., and Gasco, M. R. (1996) Influence of counter ions on the skin permeation of methotrexate from water-oil microemulsions. Pharm. Acta Helv. 71, 135-140.
472. Jansen, J. F. G. A., de Brabander-van der Berg, E. M. M., and Meijer, E. W. (1994) Encapsulation of guest molecules into a dendritic box. Science 266, 1226-1229.
473. van Hest, J. C. M., Baars, M. W. P. L., Elissen-Roman, C., van Genderen, M. H. P., and Meijer, E. W. (1995) Acid functionalized amphiphiles derived from polystyrene-polypropylene imine) dendrimers, with a pH dependent aggregation. Macromolecules 28, 6689-6691.
474. DeLong, R., Stephenson, K., Loftus, T., Fisher, M., Alahari, S., Nelting, A., and Juliano, R. L. (1997) Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. J. Pharm. Sci. 86, 762-764.
475. Loukas, Y. L. (1997) Inclusion complexation of unstable guests with cyclodextrins: improved kinetic studies for calculation of the binding constants in guest-cyclodextrin systems.Pharm. Sci. 3, 343-346.
476. Uchegbu, I. F., Gianasi, E., Cociacinch, F., Florence, A. T., and Duncan, R. (1996). Niosome encapsulation of a doxorubicin polymer conjugate. Proc. Int. Symp. Controlled Release Bioact. Mater., 23rd, 182-183.
477. Grasso, M., Morelli, A., and De Flora, A. (1986) Calcium-induced alterations in the levels and subcellular distribution of proteolytic enzymes in human red blood cells. Biochem. Biophys. Res. Commun. 138, 87-94.
478. Benatti, U., Giovine, M., Damonte, G., Gasparini, A., Scarfi, S., DeFlora, A., Fraternale, A., Rossi, L., and Magnani, M. (1996) Azidothymidine homodinucleotide-loaded erythrocytes and bioreactors for slow delivery of the antiretroviral drug azidothymidine. Biochem. Biophys. Res. Commun. 220, 20-25.